|
Evotec SE is a biopharmaceutical company that provides drug discovery and development services. The company operates through its scientific solutions and services, offering expertise in areas such as cell and gene therapy, oncology, and immunology. Evotec supports pharmaceutical and biotechnology clients by providing integrated research and development capabilities, including target identification, lead optimization, and preclinical development. The company serves customers in the global biopharmaceutical industry, facilitating the advancement of new therapeutic candidates from early discovery through to clinical stages. Evotec engages in partnerships with major life science firms to deliver customized scientific solutions. Summarised from the company's own disclosures |
Industry Biotechnology | Homepage evotec.com |
| Sector Healthcare | IR page evotec.com/ir-news | |
|
Tags
drug discovery, contract research, biopharmaceutical services, cell and gene therapy, oncology, immunology, preclinical development, target identification, Evotec
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | € 500.629M |
| Market cap (USD) | $ 550.141M |
| P/E | -2.79 |
| PEG | — |
| P/BV | — |
| P/S | 0.64 |
| P/OCF | -54.54 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | — |
| ROI | — |
| ROIC | — |
| Profit margin | -13.1% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -69.2% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
Podcast Mentions
Ad-hoc releases, corporate news and financial reports published through EQS, newest first, titles as published, directors' dealings, voting-rights notifications and buy-back reports included. The link opens the release. Material events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
· Financial performance: Q3 and nine-month Group revenue of €164.9 m and €465.0 m, respectively (Q3: €164.2 m, 9M: €477.4 m at CER); adj. Group EBITDA of -€1.6 m and -€44.3 m, respectively (Q3: -€1.7 m, 9M: -€39.1 m at CER)
· Robust commercial momentum: Net sales* in D&PD base business increased 24% vs. 9M 2025 accompanied by continued positive development across key commercial indicators.
· FY 2026 guidance reaffirmed: Expected Group revenue of €570 to €610 m (€595 to €635 m CER) and adj. Group EBITDA of -€105 to -€70 m (-€90 to -€60 m CER).
· 2030 framework further detailed: Around €1 billion in Group revenue by 2030 with further upside potential; adjusted EBITDA margin of 20% at YE 2028 and above 20% at YE 2030.
· Continued progress across differentiated platforms: Evotec confirms selection by Vertex Pharmaceuticals for commercial manufacturing of povetacicept; advancement of orthopoxvirus antibody program into Phase 1 in collaboration with DoW; new collaborations with Plectonic and Odyssey Therapeutics broaden partnered innovation activities.
4 EVOTEC EXPANDS ITS STRATEGIC RESEARCH COLLABORATION NETWORK IN IMMUNOLOGY AND ONCOLOGY; JEB ADVANCES ORTHOPOXVIRUS ANTIBODIES INTO PHASE 1 CLINICAL STUDIES
4 NINE-MONTH 2026 RESULTS ABOVE MARKET EXPECTATIONS; FULL-YEAR 2026 GUIDANCE REAFFIRMED
EVOTEC REMAINS ON TRACK TO DELIVER FULL-YEAR 2026 GUIDANCE
4 Group revenue decreased by 13.1% to € 465.0 m (9M 2025: € 535.1 m) while remaining well above expectations implied by Q3 consensus estimates and consistent with FY 2026 guidance range
4 Total D&PD revenue decreased by 11.2% to € 348.2 m (9M 2025: € 392.1 m), mainly attributable to lower sales conversion across all business areas, reflecting ongoing timing-related impacts from commercial initiatives
4 JEB revenue decreased by 18.3% to € 117.1 m (9M 2025: € 143.4 m), primarily driven by the USD 25 m Sandoz license sale recognized in Q1 2025, the timing of program-related activities and customer project progression
4 Horizon is progressing slightly ahead of schedule, supporting the delivery of the previously communicated plan to realize 20–30% of the € 75 m run-rate savings from 2027 into 2026.
Oct 29, 2026, Hamburg, Germany
Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026
====================================================================================
Hamburg, Germany, October 29, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first nine months 2026 and provide a business update on Thursday, November 5, 2026. The conference call will be held in English.
Webcast details
Date: Thursday, November 5, 2026
Time: 2.00 pm CET (1.00 pm GMT, 8.00 am EST)
To join the audio webcast and to access the presentation slides, please register via this link .
The on-demand version of the webcast will be available on our website: www.evotec.com .
Conference call details
To join the conference call, please pre-register via this link . You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.
A simultaneous slide presentation for participants dialing in via phone is available under this link .
Downloads
![]()
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of around 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec .
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact Us
+49 40 560 81 0
Follow Us
©2026, All rights reserved.
Cookies are small text files that can be used by websites to make a user's experience more efficient.
The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission.
This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
You can at any time change or withdraw your consent from the Cookie Declaration on our website.
Learn more about who we are, how you can contact us and how we process personal data in our Privacy Policy.
Please state your consent ID and date when you contact us regarding your consent.
Your consent applies to the following domains: cyprotex-store.evotec.com, aptuit.com, belab1407.org, belab2122.org, events.cyprotex.com, events.evotec.com, evotec.com, extend-tthub.com, laben2.com, news.evotec.com, rigenerand-biotech.com
Your current state: Deny.
Your current state: Do not sell or share my personal information.
Your current state: Allow selection (Necessary, Preferences, Statistics, Marketing).
Your current state: Allow all.
Your consent ID: Consent date:
Change your consent | Withdraw your consent
Do not sell or share my personal information
Cookie declaration last updated on 28/09/2026 by Cookiebot :
Necessary (60)
Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
| Name | Provider | Purpose | Maximum Storage Duration | Type |
|---|---|---|---|---|
| __cf_bm [x15] | backend.chatbase.co events.cyprotex.com events.evotec.com HubSpot hs-banner.com hubspotusercontent.com hubspotusercontent-na1.net LinkedIn news.evotec.com pancreatic.org | This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website. | 1 day | HTTP Cookie |
| _cfuvid [x5] | events.cyprotex.com events.evotec.com HubSpot news.evotec.com | This cookie is a part of the services provided by Cloudflare - Including load-balancing, deliverance of website content and serving DNS connection for website operators. | Session | HTTP Cookie |
| _GRECAPTCHA | This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website. | 180 days | HTTP Cookie | |
| 1.gif | Cookiebot | Used to count the number of sessions to the website, necessary for optimizing CMP product delivery. | Session | Pixel Tracker |
| bcookie | Used in order to detect spam and improve the website's security. | 1 year | HTTP Cookie | |
| CookieConsent [x11] | Cookiebot | Stores the user's cookie consent state for the current domain | 1 year | HTTP Cookie |
| CookieConsentPolicy | cyprotex-store.evotec.com | Stores the user's cookie consent state for the current domain | 1 year | HTTP Cookie |
| cookietest [x3] | HubSpot | This cookie is used to determine if the visitor has accepted the cookie consent box. | Session | HTTP Cookie |
| CRAFT_CSRF_TOKEN | www.evotec.com | Ensures visitor browsing-security by preventing cross-site request forgery. This cookie is essential for the security of the website and visitor. | Session | HTTP Cookie |
| CraftSessionId | www.evotec.com | Sets a unique ID for the session. This allows the website to obtain data on visitor behaviour for statistical purposes. | Session | HTTP Cookie |
| ErrorHistory#siteforce:communityApp | cyprotex-store.evotec.com | This cookie is used to detect errors on the website - this information is sent to the website's support staff in order to optimize the visitor's experience on the website. | Persistent | IndexedDB |
| li_gc | Stores the user's cookie consent state for the current domain | 180 days | HTTP Cookie | |
| LSKey-c$CookieConsentPolicy | cyprotex-store.evotec.com | Determines whether the user has accepted the cookie consent box. | 1 year | HTTP Cookie |
| PHPSESSID [x3] | EQS Group evotec-compound.mediaporta.de rigenerand-biotech.com | Preserves user session state across page requests. | Session | HTTP Cookie |
| rc::a | HubSpot | This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website. | Persistent | HTML Local Storage |
| rc::b | HubSpot | This cookie is used to distinguish between humans and bots. | Session | HTML Local Storage |
| rc::c | HubSpot | This cookie is used to distinguish between humans and bots. | Session | HTML Local Storage |
| rc::f | HubSpot | This cookie is used to distinguish between humans and bots. | Persistent | HTML Local Storage |
| renderCtx | cyprotex-store.evotec.com | Necessary to facilitate client-side-rendering, which allows the website to place website scripts in the client’s browser. | Session | HTTP Cookie |
| test_cookie | Used to check if the user's browser supports cookies. | 1 day | HTTP Cookie | |
| uncodeAI.css | rigenerand-biotech.com | Determines which device is used by the visitor - This allows the website to adjust to the optimal resolution for that specific device. | Session | HTTP Cookie |
| uncodeAI.images | rigenerand-biotech.com | Determines which device is used by the visitor - This allows the website to adjust to the optimal resolution for that specific device. | Session | HTTP Cookie |
| uncodeAI.screen | rigenerand-biotech.com | Determines which device is used by the visitor - This allows the website to adjust to the optimal resolution for that specific device. | Session | HTTP Cookie |
| wordpress_test_cookie [x2] | laben2.com rigenerand-biotech.com | Used to check if the user's browser supports cookies. | Session | HTTP Cookie |
| wpEmojiSettingsSupports [x3] | belab1407.org belab2122.org laben2.com | This cookie is part of a bundle of cookies which serve the purpose of content delivery and presentation. The cookies keep the correct state of font, blog/picture sliders, color themes and other website settings. | Session | HTML Local Storage |
Preferences (3)
Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
| Name | Provider | Purpose | Maximum Storage Duration | Type |
|---|---|---|---|---|
| CookieConsentBulkSetting-# [x2] | Cookiebot | Enables cookie consent across multiple websites | 1 year | HTML Local Storage |
| lidc | Registers which server-cluster is serving the visitor. This is used in context with load balancing, in order to optimize user experience. | 1 day | HTTP Cookie |
Statistics (35)
Statistic cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
| Name | Provider | Purpose | Maximum Storage Duration | Type |
|---|---|---|---|---|
| __hssc [x2] | HubSpot | Identifies if the cookie data needs to be updated in the visitor's browser. | 1 day | HTTP Cookie |
| __hssrc [x2] | HubSpot | Used to recognise the visitor's browser upon reentry on the website. | Session | HTTP Cookie |
| __hstc [x2] | HubSpot | Sets a unique ID for the session. This allows the website to obtain data on visitor behaviour for statistical purposes. | 180 days | HTTP Cookie |
| _ga [x3] | Registers a unique ID that is used to generate statistical data on how the visitor uses the website. | 2 years | HTTP Cookie | |
| _ga_# [x3] | Used by Google Analytics to collect data on the number of times a user has visited the website as well as dates for the first and most recent visit. | 2 years | HTTP Cookie | |
| _gat [x2] | Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels. | 1 day | HTTP Cookie | |
| _gid [x2] | Registers a unique ID that is used to generate statistical data on how the visitor uses the website. | 1 day | HTTP Cookie | |
| _pk_id# [x8] | Matomo | Collects statistics on the user's visits to the website, such as the number of visits, average time spent on the website and what pages have been read. | 1 year | HTTP Cookie |
| _pk_ref# | Matomo | Used by Piwik Analytics Platform to identify the referring website from which the visitor has come. | 6 months | HTTP Cookie |
| _pk_ses# [x8] | Matomo | Used by Piwik Analytics Platform to track page requests from the visitor during the session. | 1 day | HTTP Cookie |
| hubspotutk [x2] | HubSpot | Sets a unique ID for the session. This allows the website to obtain data on visitor behaviour for statistical purposes. | 180 days | HTTP Cookie |
Marketing (23)
Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
| Name | Provider | Purpose | Maximum Storage Duration | Type |
|---|---|---|---|---|
| #,# | Collects data on user behaviour and interaction in order to optimize the website and make advertisement on the website more relevant. | Persistent | HTML Local Storage | |
| #,#_expiresAt | Collects data on user behaviour and interaction in order to optimize the website and make advertisement on the website more relevant. | Persistent | HTML Local Storage | |
| __ptq.gif | HubSpot | Sends data to the marketing platform Hubspot about the visitor's device and behaviour. Tracks the visitor across devices and marketing channels. | Session | Pixel Tracker |
| __Secure-ROLLOUT_TOKEN | YouTube | Used to track user’s interaction with embedded content. | 180 days | HTTP Cookie |
| __Secure-YEC | YouTube | Stores the user's video player preferences using embedded YouTube video | Session | HTTP Cookie |
| __Secure-YNID | YouTube | Used to track user’s interaction with embedded content. | 180 days | HTTP Cookie |
| _gcl_au | Used by Google AdSense for experimenting with advertisement efficiency across websites using their services. | 3 months | HTTP Cookie | |
| _gcl_ls | Tracks the conversion rate between the user and the advertisement banners on the website - This serves to optimise the relevance of the advertisements on the website. | Persistent | HTML Local Storage | |
| GlobalValueProviders__MUTEX_X | cyprotex-store.evotec.com | Used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences. | Persistent | HTML Local Storage |
| LAST_RESULT_ENTRY_KEY [x2] | YouTube | Used to track user’s interaction with embedded content. | Session | HTTP Cookie |
| LogsDatabaseV2:V#|LogsRequestsStore | YouTube | Used to track user’s interaction with embedded content. | Persistent | IndexedDB |
| pagead/1p-user-list/# | Tracks if the user has shown interest in specific products or events across multiple websites and detects how the user navigates between sites. This is used for measurement of advertisement efforts and facilitates payment of referral-fees between websites. | Session | Pixel Tracker | |
| pctrk | cyprotex-store.evotec.com | Tracks the individual sessions on the website, allowing the website to compile statistical data from multiple visits. This data can also be used to create leads for marketing purposes. | 1 year | HTTP Cookie |
| TESTCOOKIESENABLED [x2] | YouTube | Used to track user’s interaction with embedded content. | 1 day | HTTP Cookie |
| VISITOR_INFO1_LIVE | YouTube | Tries to estimate the users' bandwidth on pages with integrated YouTube videos. | 180 days | HTTP Cookie |
| YSC | YouTube | Registers a unique ID to keep statistics of what videos from YouTube the user has seen. | Session | HTTP Cookie |
| yt-icons-last-purged [x2] | YouTube | Necessary for the implementation and functionality of YouTube video-content on the website. | Persistent | HTML Local Storage |
| ytidb::LAST_RESULT_ENTRY_KEY | YouTube | Used to track user’s interaction with embedded content. | Persistent | HTML Local Storage |
| YtIdbMeta#databases [x2] | YouTube | Used to track user’s interaction with embedded content. | Persistent | IndexedDB |
Unclassified (5)
Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
| Name | Provider | Purpose | Maximum Storage Duration | Type |
|---|---|---|---|---|
| ##communityApp ~ #/s ~ # | cyprotex-store.evotec.com | Pending | Persistent | IndexedDB |
| chatbase_anon_id | www.chatbase.co | Pending | Session | HTTP Cookie |
| gatesUnlocked | www.evotec.com | Pending | Persistent | HTML Local Storage |
| message_bubbles_have_been_shown | www.chatbase.co | Pending | Session | HTML Local Storage |
| yt-player-caption-persistence | YouTube | Pending | Persistent | HTML Local Storage |
Stock Information | Evotec
-
-
-
Solutions
-
Company
-
IR & News
back
-
-
…
-
Stock Information

Stock Information
Latest Analyst Recommendations
Stock Information
Latest Analyst Recommendations
Latest Analyst Recommendations
Stock Information
Latest Analyst Recommendations
In this section you will find detailed information regarding the Evotec SE share, such as basic share data over share price summary, stock price and charts, our financial analysts and their latest recommendations, and our dividend policy.
Share Buy Back Program for Employees (November 2025)
Basic Share Data
| Listing on Frankfurt Stock Exchange (XETRA) | Listing NASDAQ, New York | |
|---|---|---|
| Security identification numbers | Ordinary bearer shares ISIN: DE0005664809 | American Depositary Shares (“ADSs”) ISIN: US30050E1055 |
| Ticker symbol | Frankfurt Stock Exchange: EVT | NASDAQ: EVO Bloomberg Xetra: EVT GY Equity Reuters Xetra: EVTG.DE |
| Stock exchange | Frankfurt Stock Exchange | NASDAQ New York |
| Segment | Prime Standard | Global Select Market |
| Index | SDAX, TecDAX, Prime All Share, LTecDAX, Technology All Share, CDAX | n/a |
| Designated Sponsor | ODDO SEYDLER BANK AG | |
| Paying agent | Deutsche Bank AG, Frankfurt am Main | J.P. Morgan |
| Number of shares issued | 177,909,968 ordinary bearer shares | 22,995,000 ADSs (11,497,500 ordinary shares) |
| Nominal capital | € 177,909,968 | € 177,909,968 |
Listing on NASDAQ
Since November 2021 Evotec SE is listed on NASDAQ (Ticker Symbol: EVO).
Please find all further information regarding the NASDAQ listing as well as all published filings of Evotec SE here .
Stock Price & Chart
Analysts
Overview of analysts covering the Evotec share.

Berenberg
Dr. Christian Ehmann
Latest update: September 2026
Dr. Christian Ehmann
Bockenheimer Landstraße 25
60325 Frankfurt am Main

BNP Paribas
Mohamed Kaabouni
Latest update: September 2026
Mohamed Kaabouni
13 rue de la Brasserie
44100 Nantes
France

TD Cowen
Chad Wiatrowski
Latest update: September 2026
Chad Wiatrowski
One Vanderbilt Avenue
New York, NY 10017
United States Of America

Deutsche Bank
Fynn Scherzler
Latest update: September 2026
Fynn Scherzler
Große Gallusstraße 10-14
Frankfurt am Main 60311
Germany

EQUI.TS GmbH
Thomas Schiessle
Latest update: April 2025
Thomas Schiessle
AM Schieferstein 1
Frankfurt am Main 60435
Germany

H.C. Wainwright & Co.
Swayampakula Ramakanth
Latest update: September 2026
Swayampakula Ramakanth
430 Park Avenue.
New York City, NY 10022
United States of America

Intron Health
Naresh Chouhan
Latest update: September 2026
Naresh Chouhan
11 Austin Friars
London EC2N 2HG
United Kingdom

ODDO BHF
Stephan Wulf
Latest update: September 2026
Stephan Wulf
Gallusanlage 8
60323 Frankfurt am Main
Germany

Royal Bank of Canada (RBC)
Charles Weston
Latest update: September 2026
Charles Weston
100 Bishopsgate
London, EC2N 4AA,
United Kingdon

Van Lanschot Kempen
Sebastiaan van der Schoot
Latest update: September 2026
Sebastiaan van der Schoot
Beethovenstraat 300
Amsterdam 1077 WZ
Netherlands
Latest Analyst Recommendations
Below you will find the latest analyst recommendations.
| Analyst | Recommendation | Target price of Shares listed at Frankfurt Stock Exchange (in EUR) | Target Price of ADS listed at NASDAQ New York (in USD) | Date of Latest Research Report |
|---|---|---|---|---|
| Berenberg | HOLD | 3.60 EUR | - | September 24, 2026 |
| BNP Paribas Group | HOLD | 3.50 EUR | - | August 13, 2026 |
| TD Cowen | HOLD | 3.00 EUR | 2.00 USD | October 14, 2026 |
| Deutsche Bank | HOLD | 3.50 EUR | - | October 14, 2026 |
| H.C.Wainwright & Co | BUY | - | 4.00 USD | August 14, 2026 |
| IntronHealth | SELL | 2.00 EUR | - | March 11, 2026 |
| ODDO BHF | NEUTRAL | 3.50 EUR | - | October 14, 2026 |
| Royal Bank of Canada (RBC) | OUTPERFORM | 10.00 EUR | - | October 14, 2026 |
| Van Lanschot Kempen | NEUTRAL | 4.00 EUR | - | October 14, 2026 |
| Average target price | 4.14 EUR | 3.00 USD |
Important Notice:
Evotec is covered and evaluated by the analysts mentioned above. Please note that any opinions, estimates or forecasts regarding Evotec's performance made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Evotec or its management. The above reference to the analysts does not imply that Evotec endorses their opinions. Evotec is under no obligation to update or supplement the information provided above and does not guarantee the accuracy or completeness of this list.
Copies of the reports from the analysts listed above can be obtained directly from the analysts or their employers. Due to legal requirements, Evotec is not allowed to publish the analyst reports.
Evotec's Dividend Policy
The payment of dividends depends on Evotec’s financial situation and liquidity requirements, general market conditions, and statutory, tax and regulatory requirements.
Evotec has never paid or declared any cash dividends on its ordinary shares, and does not anticipate paying any cash dividends on its ordinary shares in the foreseeable future. Evotec intends to retain all available funds and any future earnings and reinvest them in the company’s further growth strategy to better leverage long-term growth and sustainability.
Under German law, Evotec may pay dividends only from the distributable profit (Bilanzgewinn) reflected in its unconsolidated financial statements (as opposed to the consolidated financial statements for Evotec and its subsidiaries) prepared in accordance with the principles set forth in the German Commercial Code (Handelsgesetzbuch) and adopted by the Evotec Management Board (Vorstand) and the Supervisory Board (Aufsichtsrat), or, as the case may be, by the shareholders of Evotec in a general shareholders’ meeting. In addition, under German law Evotec may not pay dividends before annual profits exceed the losses carried forward.
All of the shares represented by the ADSs offered in USA generally have the same dividend rights as all of Evotec's other outstanding shares.
Oct 15, 2026, Hamburg, Germany
Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board
======================================================================================================
- Will lead Evotec’s global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovation.
- Brings more than 25 years of global experience in pharma, biotechnology and academia
Hamburg, Germany, October 15, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the appointment of Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board, effective November 1, 2026. Dr. Holbrook brings to Evotec more than 25 years of experience as both a scientist and R&D leader, applying novel technologies and data approaches to the challenges of drug discovery and advancing programs toward the clinic. Her experience spans multi-modal ‘omics, data science, novel therapeutic modalities and precision medicine, complemented by experience in commercializing innovative technologies, shaping drug discovery partnerships and leading therapeutic research portfolios. At Evotec, Dr. Holbrook will draw on recent scientific advances to help customers and partners discover and develop new medicines faster and with a higher probability of success.
Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:
“Joanna has a keen understanding of how data, AI and new technologies are transforming drug discovery and development today. She combines this forward-looking perspective with deep scientific expertise and a strong focus on generating robust, actionable results. I look forward to working with her as we continue to strengthen Evotec’s position as a leading partner for any organization that strives to bring new, groundbreaking medicines to market.”
Dr. Holbrook most recently served as Therapy Area Head, Cardiovascular, Renal and Hepatic Disease and Head of in vitro Discovery Platforms at Novo Nordisk. Prior to that she held positions at UK biotech companies Biomodal, where she served as Chief Scientific Officer, and BenevolentAI, where she was Vice President, Translational Medicine. She was also Professor of Bioinformatics at the University of Southampton and Senior Principal Investigator at the Singapore Institute for Clinical Sciences (A*STAR) and adjunct Professor at National University of Singapore. She started her career at GSK, where she held positions of increasing responsibility across therapy areas and bioinformatics. She holds a Ph.D. in Molecular Cell Biology from University College London and a B.Sc. in Genetics from the University of Newcastle.
Dr. Joanna Holbrook, Evotec’s incoming Chief Scientific Officer, added:
“Evotec has exceptional breadth of scientific expertise and capabilities spanning drug discovery, drug development and manufacturing. I am excited by the opportunity to work across the business to strengthen our scientific differentiation, build integrated solutions to the most important challenges in drug discovery, and develop new capabilities that are unique to Evotec.”
Downloads
![]()
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of around 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec .
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact Us
+49 40 560 81 0
Follow Us
©2026, All rights reserved.
Evotec SE today announced the appointment of Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board, effective November 1, 2026. Dr. Holbrook brings to Evotec more than 25 years of experience as both a scientist and R&D …
Ad Hoc
Oct 13, 2026
Hamburg, Germany
Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance
Hamburg, Germany – Evotec SE today announced preliminary unaudited financial results for first nine months of 2026. Full financial results for the third quarter and the first nine months of 2026 will be published on November 5, 2026, as scheduled.
News
Sep 29, 2026
Hamburg, Germany
Evotec Announces Chief Scientific Officer Transition
Evotec SE today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective September 30, 2026. The decision for Dr. Dohrmann to step down from his position was made by mutual consent between Dr. Dohrmann and the Company.
News
Sep 09, 2026
Hamburg, Germany
Just – Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies
Evotec SE today announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its biologics CDMO subsidiary Just – Evotec Biologics under the …
Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance
Hamburg, Germany – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for first nine months of 2026. Full financial results for the third quarter and the first nine months of 2026 will be published on November 5, 2026, as scheduled.
Based on preliminary figures, Evotec expects Group revenues for the first nine months of 2026 of approximately €465.0 million and adjusted Group EBITDA of approximately -€42.8 million. These figures are above current market expectations, with the variance driven largely by the phasing of consensus estimates.
Evotec reaffirms its full-year 2026 guidance, which projects Group revenues of approximately €570 to €610 million (€595 to €635 million at CER) and adjusted Group EBITDA of approximately -€70 to -€105 million (-€60 to -€90 million at CER).
– End of the ad hoc release –
Cookies are small text files that can be used by websites to make a user's experience more efficient.
The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission.
This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
You can at any time change or withdraw your consent from the Cookie Declaration on our website.
Learn more about who we are, how you can contact us and how we process personal data in our Privacy Policy.
Please state your consent ID and date when you contact us regarding your consent.
Your consent applies to the following domains: cyprotex-store.evotec.com, aptuit.com, belab1407.org, belab2122.org, events.cyprotex.com, events.evotec.com, evotec.com, extend-tthub.com, laben2.com, news.evotec.com, rigenerand-biotech.com
Your current state: Deny.
Your current state: Do not sell or share my personal information.
Your current state: Allow selection (Necessary, Preferences, Statistics, Marketing).
Your current state: Allow all.
Your consent ID: Consent date:
Change your consent | Withdraw your consent
Do not sell or share my personal information
Cookie declaration last updated on 28/10/2026 by Cookiebot :
Necessary (60)
Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
| Name | Provider | Purpose | Maximum Storage Duration | Type |
|---|---|---|---|---|
| __cf_bm [x15] | backend.chatbase.co events.cyprotex.com events.evotec.com HubSpot hs-banner.com hubspotusercontent.com hubspotusercontent-na1.net LinkedIn news.evotec.com pancreatic.org | This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website. | 1 day | HTTP Cookie |
| _cfuvid [x5] | events.cyprotex.com events.evotec.com HubSpot news.evotec.com | This cookie is a part of the services provided by Cloudflare - Including load-balancing, deliverance of website content and serving DNS connection for website operators. | Session | HTTP Cookie |
| _GRECAPTCHA | This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website. | 180 days | HTTP Cookie | |
| 1.gif | Cookiebot | Used to count the number of sessions to the website, necessary for optimizing CMP product delivery. | Session | Pixel Tracker |
| bcookie | Used in order to detect spam and improve the website's security. | 1 year | HTTP Cookie | |
| CookieConsent [x11] | Cookiebot | Stores the user's cookie consent state for the current domain | 1 year | HTTP Cookie |
| CookieConsentPolicy | cyprotex-store.evotec.com | Stores the user's cookie consent state for the current domain | 1 year | HTTP Cookie |
| cookietest [x3] | HubSpot | This cookie is used to determine if the visitor has accepted the cookie consent box. | Session | HTTP Cookie |
| CRAFT_CSRF_TOKEN | www.evotec.com | Ensures visitor browsing-security by preventing cross-site request forgery. This cookie is essential for the security of the website and visitor. | Session | HTTP Cookie |
| CraftSessionId | www.evotec.com | Sets a unique ID for the session. This allows the website to obtain data on visitor behaviour for statistical purposes. | Session | HTTP Cookie |
| ErrorHistory#siteforce:communityApp | cyprotex-store.evotec.com | This cookie is used to detect errors on the website - this information is sent to the website's support staff in order to optimize the visitor's experience on the website. | Persistent | IndexedDB |
| li_gc | Stores the user's cookie consent state for the current domain | 180 days | HTTP Cookie | |
| LSKey-c$CookieConsentPolicy | cyprotex-store.evotec.com | Determines whether the user has accepted the cookie consent box. | 1 year | HTTP Cookie |
| PHPSESSID [x3] | EQS Group evotec-compound.mediaporta.de rigenerand-biotech.com | Preserves user session state across page requests. | Session | HTTP Cookie |
| rc::a | HubSpot | This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website. | Persistent | HTML Local Storage |
| rc::b | HubSpot | This cookie is used to distinguish between humans and bots. | Session | HTML Local Storage |
| rc::c | HubSpot | This cookie is used to distinguish between humans and bots. | Session | HTML Local Storage |
| rc::f | HubSpot | This cookie is used to distinguish between humans and bots. | Persistent | HTML Local Storage |
| renderCtx | cyprotex-store.evotec.com | Necessary to facilitate client-side-rendering, which allows the website to place website scripts in the client’s browser. | Session | HTTP Cookie |
| test_cookie | Used to check if the user's browser supports cookies. | 1 day | HTTP Cookie | |
| uncodeAI.css | rigenerand-biotech.com | Determines which device is used by the visitor - This allows the website to adjust to the optimal resolution for that specific device. | Session | HTTP Cookie |
| uncodeAI.images | rigenerand-biotech.com | Determines which device is used by the visitor - This allows the website to adjust to the optimal resolution for that specific device. | Session | HTTP Cookie |
| uncodeAI.screen | rigenerand-biotech.com | Determines which device is used by the visitor - This allows the website to adjust to the optimal resolution for that specific device. | Session | HTTP Cookie |
| wordpress_test_cookie [x2] | laben2.com rigenerand-biotech.com | Used to check if the user's browser supports cookies. | Session | HTTP Cookie |
| wpEmojiSettingsSupports [x3] | belab1407.org belab2122.org laben2.com | This cookie is part of a bundle of cookies which serve the purpose of content delivery and presentation. The cookies keep the correct state of font, blog/picture sliders, color themes and other website settings. | Session | HTML Local Storage |
Preferences (3)
Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
| Name | Provider | Purpose | Maximum Storage Duration | Type |
|---|---|---|---|---|
| CookieConsentBulkSetting-# [x2] | Cookiebot | Enables cookie consent across multiple websites | 1 year | HTML Local Storage |
| lidc | Registers which server-cluster is serving the visitor. This is used in context with load balancing, in order to optimize user experience. | 1 day | HTTP Cookie |
Statistics (35)
Statistic cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
| Name | Provider | Purpose | Maximum Storage Duration | Type |
|---|---|---|---|---|
| __hssc [x2] | HubSpot | Identifies if the cookie data needs to be updated in the visitor's browser. | 1 day | HTTP Cookie |
| __hssrc [x2] | HubSpot | Used to recognise the visitor's browser upon reentry on the website. | Session | HTTP Cookie |
| __hstc [x2] | HubSpot | Sets a unique ID for the session. This allows the website to obtain data on visitor behaviour for statistical purposes. | 180 days | HTTP Cookie |
| _ga [x3] | Registers a unique ID that is used to generate statistical data on how the visitor uses the website. | 2 years | HTTP Cookie | |
| _ga_# [x3] | Used by Google Analytics to collect data on the number of times a user has visited the website as well as dates for the first and most recent visit. | 2 years | HTTP Cookie | |
| _gat [x2] | Used by Google Analytics to throttle request rate | 1 day | HTTP Cookie | |
| _gid [x2] | Registers a unique ID that is used to generate statistical data on how the visitor uses the website. | 1 day | HTTP Cookie | |
| _pk_id# [x8] | Matomo | Collects statistics on the user's visits to the website, such as the number of visits, average time spent on the website and what pages have been read. | 1 year | HTTP Cookie |
| _pk_ref# | Matomo | Used by Piwik Analytics Platform to identify the referring website from which the visitor has come. | 6 months | HTTP Cookie |
| _pk_ses# [x8] | Matomo | Used by Piwik Analytics Platform to track page requests from the visitor during the session. | 1 day | HTTP Cookie |
| hubspotutk [x2] | HubSpot | Sets a unique ID for the session. This allows the website to obtain data on visitor behaviour for statistical purposes. | 180 days | HTTP Cookie |
Marketing (25)
Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
| Name | Provider | Purpose | Maximum Storage Duration | Type |
|---|---|---|---|---|
| #,# | Collects data on user behaviour and interaction in order to optimize the website and make advertisement on the website more relevant. | Persistent | HTML Local Storage | |
| #,#_expiresAt | Collects data on user behaviour and interaction in order to optimize the website and make advertisement on the website more relevant. | Persistent | HTML Local Storage | |
| __ptq.gif | HubSpot | Sends data to the marketing platform Hubspot about the visitor's device and behaviour. Tracks the visitor across devices and marketing channels. | Session | Pixel Tracker |
| __Secure-BUCKET | YouTube | Pending | 180 days | HTTP Cookie |
| __Secure-ROLLOUT_TOKEN | YouTube | Used to track user’s interaction with embedded content. | 180 days | HTTP Cookie |
| __Secure-YEC | YouTube | Stores the user's video player preferences using embedded YouTube video | Session | HTTP Cookie |
| __Secure-YNID | YouTube | Used to track user’s interaction with embedded content. | 180 days | HTTP Cookie |
| _gcl_au | Used by Google AdSense for experimenting with advertisement efficiency across websites using their services. | 3 months | HTTP Cookie | |
| _gcl_ls | Tracks the conversion rate between the user and the advertisement banners on the website - This serves to optimise the relevance of the advertisements on the website. | Persistent | HTML Local Storage | |
| GlobalValueProviders__MUTEX_X | cyprotex-store.evotec.com | Used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences. | Persistent | HTML Local Storage |
| LAST_RESULT_ENTRY_KEY [x2] | YouTube | Used to track user’s interaction with embedded content. | Session | HTTP Cookie |
| LogsDatabaseV2:V#|LogsRequestsStore | YouTube | Used to track user’s interaction with embedded content. | Persistent | IndexedDB |
| pagead/1p-user-list/# | Tracks if the user has shown interest in specific products or events across multiple websites and detects how the user navigates between sites. This is used for measurement of advertisement efforts and facilitates payment of referral-fees between websites. | Session | Pixel Tracker | |
| pctrk | cyprotex-store.evotec.com | Tracks the individual sessions on the website, allowing the website to compile statistical data from multiple visits. This data can also be used to create leads for marketing purposes. | 1 year | HTTP Cookie |
| ServiceWorkerLogsDatabase#SWHealthLog | YouTube | Necessary for the implementation and functionality of YouTube video-content on the website. | Persistent | IndexedDB |
| TESTCOOKIESENABLED [x2] | YouTube | Used to track user’s interaction with embedded content. | 1 day | HTTP Cookie |
| VISITOR_INFO1_LIVE | YouTube | Tries to estimate the users' bandwidth on pages with integrated YouTube videos. | 180 days | HTTP Cookie |
| YSC | YouTube | Registers a unique ID to keep statistics of what videos from YouTube the user has seen. | Session | HTTP Cookie |
| yt-icons-last-purged [x2] | YouTube | Necessary for the implementation and functionality of YouTube video-content on the website. | Persistent | HTML Local Storage |
| ytidb::LAST_RESULT_ENTRY_KEY | YouTube | Used to track user’s interaction with embedded content. | Persistent | HTML Local Storage |
| YtIdbMeta#databases [x2] | YouTube | Used to track user’s interaction with embedded content. | Persistent | IndexedDB |
Unclassified (5)
Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
| Name | Provider | Purpose | Maximum Storage Duration | Type |
|---|---|---|---|---|
| ##communityApp ~ #/s ~ # | cyprotex-store.evotec.com | Pending | Persistent | IndexedDB |
| chatbase_anon_id | www.chatbase.co | Pending | Session | HTTP Cookie |
| gatesUnlocked | www.evotec.com | Pending | Persistent | HTML Local Storage |
| message_bubbles_have_been_shown | www.chatbase.co | Pending | Session | HTML Local Storage |
| yt-player-caption-persistence | YouTube | Pending | Persistent | HTML Local Storage |
Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance - Evotec
-
-
-
Solutions
-
Company
-
IR & News
back
-
-
…
-
Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance
Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance
Hamburg, Germany – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for first nine months of 2026. Full financial results for the third quarter and the first nine months of 2026 will be published on November 5, 2026, as scheduled.
Based on preliminary figures, Evotec expects Group revenues for the first nine months of 2026 of approximately €465.0 million and adjusted Group EBITDA of approximately -€42.8 million. These figures are above current market expectations, with the variance driven largely by the phasing of consensus estimates.
Evotec reaffirms its full-year 2026 guidance, which projects Group revenues of approximately €570 to €610 million (€595 to €635 million at CER) and adjusted Group EBITDA of approximately -€70 to -€105 million (-€60 to -€90 million at CER).
Contact Us
+49 40 560 81 0
Follow Us
©2026, All rights reserved.
Sep 29, 2026, Hamburg, Germany
Evotec Announces Chief Scientific Officer Transition
========================================================
- Dr. Cord Dohrmann to step down as of September 30, 2026
- Search ongoing for a successor
Hamburg, Germany, September 29, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective September 30, 2026. The decision for Dr. Dohrmann to step down from his position was made by mutual consent between Dr. Dohrmann and the Company.
Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:
“I would like to thank Cord for his long service and many contributions to Evotec over the past 16 years. Throughout his tenure, he has played a significant role in strengthening the scientific excellence and innovation culture that Evotec is known for. With his strategic vision for emerging technologies and future scientific trends, Cord has helped establish key capabilities across our platforms, including our iPSC-based technologies and omics capabilities, which have further reinforced Evotec’s scientific leadership. Looking to the future, the robust science infrastructure that Cord has built will be an essential component of Evotec’s future growth and profitability.”
Dr. Cord Dohrmann, Evotec’s outgoing Chief Scientific Officer, added:
“The process of advancing new therapies from discovery to the clinic has evolved significantly over the past 16 years, and I have been privileged to contribute to that progress during my time at Evotec. I am grateful for the support and collaboration of the many colleagues I have worked with in that time and look forward to seeing Evotec’s scientific expertise continue to create value for customers, partners and patients.”
Dr. Dohrmann has served as Chief Scientific Officer and Member of the Management Board since 2010. The search for his replacement is ongoing.
Downloads
![]()
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of around 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec .
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact Us
+49 40 560 81 0
Follow Us
©2026, All rights reserved.
Sep 9, 2026, Hamburg, Germany
Just – Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies
==========================================================================================================================
- First-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies Program
- Supports development of countermeasures against orthopoxviruses, a high-priority biological threat family that includes viruses responsible for smallpox
- Delivers integrated process development, regulatory submission and manufacturing of clinical trial material at J.POD® Redmond facility
- Demonstrates scalable model for development and continuous manufacturing for biodefense preparedness
Seattle, WA, USA / Hamburg, Germany, September 9, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its biologics CDMO subsidiary Just – Evotec Biologics under the U.S. Department of War’s Accelerated Antibodies Program.
Under the Accelerated Antibodies Program, Just – Evotec Biologics advanced the orthopoxvirus program from antibody sequence selection through preclinical development, process development, regulatory submission and cGMP manufacture of clinical trial materials. Manufacturing was completed at the company’s J.POD® facility in Redmond, Washington, utilizing its continuous bioprocessing platform.
This milestone delivers on the scope of Just – Evotec Biologics’ 2023 contract with the U.S. Department of War to progress antibody-based drug candidates against orthopoxviruses from continuous manufacturing process development through first-in-human clinical evaluation. The investigational antibody, JST-018, is being developed as a prophylactic therapy intended to help protect warfighters who may face an elevated risk of exposure to biological threats.
Linda Zuckerman, PhD, EVP Global Head of Just – Evotec Biologics, said:
“This program exemplifies the power of our integrated continuous manufacturing platform for biologics to advance seamlessly from sequence optimization to clinical evaluation. Through close collaboration with the Department of War, we manufactured and delivered JST-018 as an urgently needed medical countermeasure for the U.S. government under the Accelerated Antibodies Program.”
Orthopoxviruses include the variola virus, which causes smallpox, as well as the virus responsible for mpox. The virus family remains an important focus of biodefense and global public health preparedness. The continuous manufacturing platform at Just – Evotec Biologics provides a rapid and cost-effective approach for these important medical countermeasures.
The orthopoxvirus program is Just – Evotec Biologics’ second under the U.S. Department of War’s Accelerated Antibodies Program, following an initial 2022 program award to support the development of monoclonal antibodies against plague. Together, the two previously announced contracts have a combined potential value of up to $123.9 million.
The orthopoxvirus contract was awarded to Just – Evotec Biologics in 2023 by the U.S. Department of War’s Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE-CBRND), in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), through the Medical CBRN Defense Consortium (MCDC) Other Transaction Authority, under contract number MCDC2203-001. Reference to the Department of War, CPE-CBRND, or other agency of the United States does not constitute or imply an endorsement or recommendation by the United States Government or any agency thereof.
Additional information regarding the study is available on ClinicalTrials.gov (NCT07595458).
Downloads
![]()
About Just – Evotec Biologics, Inc.
Just – Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform company that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at www.just-evotecbiologics.com.
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of around 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec .
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Investor Relations and Media Contact
Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
[email protected]
Contact Us
+49 40 560 81 0
Follow Us
©2026, All rights reserved.
Sep 2, 2026, Hamburg, Germany, and Hallbergmoos, Germany
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
==============================================================================================================================
- Collaboration aims to validate Evotec’s proprietary BiTco costimulatory CD2 bispecifics platform in combination with Plectonic’s logic-gated DNA-protein immunotherapy technology LOGIBODY®
- BiTco designed to boost T cell activation by engaging a costimulatory signaling pathway
- LOGIBODY® designed to enhance precision of T cell activation based on multispecific antigen signature
Hamburg, Germany, and Hallbergmoos, Germany, September 2, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) and Plectonic Biotech today announced a research collaboration to explore a novel immunotherapy approach for solid tumors. The collaboration addresses key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumors by combining Plectonic’s programmable LOGIBODY® technology with Evotec’s proprietary BiTco platform.
Plectonic’s LOGIBODY® technology engineers DNA-protein therapeutics designed to recognize tumors through a highly specific combination of tumor-associated antigens before engaging T cells. Unlike conventional T cell engagers, LOGIBODY® molecules require simultaneous binding to a predefined multi-antigen tumor signature to trigger T cell activation. This logic-gated approach represents a novel drug class aimed at improving treatment precision, reducing activation in healthy tissues and potentially broadening the therapeutic window.
Evotec’s BiTco platform is based on a proprietary, non-blocking CD2 antibody designed to provide an additional costimulatory signal to T cells, enhancing their activity and persistence within the tumor microenvironment. The antibody targets a unique CD2 epitope while preserving its natural interactions, enabling BiTco to strengthen T cell responses, enhance tumor cell killing mediated by T cell engagers, and delay T cell exhaustion.
By combining highly selective tumor recognition and enhanced T-cell activation, the companies will explore whether their integrated technologies can improve both the precision and potency of T-cell-engaging approaches in solid tumors. Under the terms of the agreement, the collaboration will generate preclinical proof-of-concept data to evaluate the potential of this new generation of T-cell-engaging approaches.
Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said:
“T cell engagers have demonstrated significant promise in oncology in blood cancers, yet challenges remain in extending their clinical success to solid tumors, which represent approximately 90 percent of all cancers. Through this collaboration, we aim to evaluate the potential of combining our proprietary BiTco platform with Plectonic’s LOGIBODY® technology and explore new strategies to enhance T cell engager activity in solid tumors. Our CD2-based co-stimulation approach is an ideal component for this effort or any TCE development strategy that seeks an effective source of T cell co-stimulation in the solid tumor setting.”
Dr. Klaus Wagenbauer, CEO and Founder of Plectonic Biotech, added:
“This collaboration with Evotec highlights the broad potential and modularity of our LOGIBODY® technology to engineer logic-gated T-cell-engaging biologics and explore novel multi-specific designs. By combining our complementary technologies, we have the opportunity to enable highly precise and controlled immune activation at the tumor. Together, we look forward to investigating this next-generation modality and exploring new ways to address long-standing challenges in tumor selectivity and safety that have limited the effectiveness of T cell engagers in solid tumor indications.”
Plectonic has demonstrated the modularity of its LOGIBODY® technology in preclinical studies across both liquid and solid tumors, utilizing dual-targeting and co-stimulatory therapeutic strategies. Evotec recently published preclinical research on its BiTco platform, providing proof-of-concept for CD2-mediated T cell co-stimulation in combination with T cell engager approaches.
Downloads
![]()
About Plectonic Biotech
Plectonic Biotech’s new class of programmable DNA-protein therapeutics function as molecular logic gates to selectively direct the immune response to the tumor. By applying our modular LOGIBODY® platform, we are building a pipeline of multi-specific T-cell-engaging biologics designed to overcome off-target toxicity and exponentially improve the therapeutic impact of immunotherapies using clinically validated targets. Initially focused on hematologic malignancies, our approach is designed to deliver an unprecedented level of precision and control, broadening the therapeutic window and improving patient outcomes in both liquid and solid tumors.
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of around 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec .
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Evotec Investor Relations and Media Contact
Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
[email protected]
Plectonic Media Contact
Trophic Communications
Joe Rayne or Stephanie May
[email protected]
+49 171 185 5682
Contact Us
+49 40 560 81 0
Follow Us
©2026, All rights reserved.
4 JUST – EVOTEC BIOLOGICS (“JEB”) SHOWED CONTINUED PROGRESS WITH HIGH CAPACITY UTILIZATION AND EXPANDED CUSTOMER BASE
4 HORIZON TRANSFORMATION ON TRACK: OPERATIONAL AND COST INITIATIVES PROGRESSING AS PLANNED
4 JEB LAUNCHED J.TRAIN TURNKEY CONTINUOUS MANUFACTURING; EVOTEC ADVANCED AN ALMIRALL DERMATOLOGY DRUG CANDIDATE PRE-CLINICALLY
4 FY 2026 OUTLOOK UPDATED, REFLECTING PARTNERSHIP TIMING SHIFTS AND LOWER REVENUE CONVERSION
H1 RESULTS IMPACTED BY CHALLENGING MARKET CONDITIONS AND REVENUE TIMING EFFECTS DESPITE POSITIVE COMMERCIAL EXECUTION
4 Total D&PD revenue decreased by 15.2% to € 228.1 m (6M 2025: € 269.0 m), primarily driven by weak sales to revenue conversion across all business areas;
Just – Evotec Biologics revenue decreased by 29.3% to € 72.3 m (6M 2025: € 102.2 m) primarily driven by the Sandoz License sale in Q1 2025
4 Adjusted Group EBITDA totaled € (42.7) m (6M 2025: € (1.9) m) primarily driven by lower revenues, partly offset by reduced cost of revenue as well as lower R&D and SG&A expenses
1 Net sales are defined as signed work orders, positive change orders and negative change orders.
Cookies are small text files that can be used by websites to make a user's experience more efficient.
The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission.
This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
You can at any time change or withdraw your consent from the Cookie Declaration on our website.
Learn more about who we are, how you can contact us and how we process personal data in our Privacy Policy.
Please state your consent ID and date when you contact us regarding your consent.
Your consent applies to the following domains: cyprotex-store.evotec.com, aptuit.com, belab1407.org, belab2122.org, events.cyprotex.com, events.evotec.com, evotec.com, extend-tthub.com, laben2.com, news.evotec.com, rigenerand-biotech.com
Your current state: Deny.
Your current state: Do not sell or share my personal information.
Your current state: Allow selection (Necessary, Preferences, Statistics, Marketing).
Your current state: Allow all.
Your consent ID: Consent date:
Change your consent | Withdraw your consent
Do not sell or share my personal information
Cookie declaration last updated on 28/09/2026 by Cookiebot :
Necessary (60)
Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
| Name | Provider | Purpose | Maximum Storage Duration | Type |
|---|---|---|---|---|
| __cf_bm [x15] | backend.chatbase.co events.cyprotex.com events.evotec.com HubSpot hs-banner.com hubspotusercontent.com hubspotusercontent-na1.net LinkedIn news.evotec.com pancreatic.org | This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website. | 1 day | HTTP Cookie |
| _cfuvid [x5] | events.cyprotex.com events.evotec.com HubSpot news.evotec.com | This cookie is a part of the services provided by Cloudflare - Including load-balancing, deliverance of website content and serving DNS connection for website operators. | Session | HTTP Cookie |
| _GRECAPTCHA | This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website. | 180 days | HTTP Cookie | |
| 1.gif | Cookiebot | Used to count the number of sessions to the website, necessary for optimizing CMP product delivery. | Session | Pixel Tracker |
| bcookie | Used in order to detect spam and improve the website's security. | 1 year | HTTP Cookie | |
| CookieConsent [x11] | Cookiebot | Stores the user's cookie consent state for the current domain | 1 year | HTTP Cookie |
| CookieConsentPolicy | cyprotex-store.evotec.com | Stores the user's cookie consent state for the current domain | 1 year | HTTP Cookie |
| cookietest [x3] | HubSpot | This cookie is used to determine if the visitor has accepted the cookie consent box. | Session | HTTP Cookie |
| CRAFT_CSRF_TOKEN | www.evotec.com | Ensures visitor browsing-security by preventing cross-site request forgery. This cookie is essential for the security of the website and visitor. | Session | HTTP Cookie |
| CraftSessionId | www.evotec.com | Sets a unique ID for the session. This allows the website to obtain data on visitor behaviour for statistical purposes. | Session | HTTP Cookie |
| ErrorHistory#siteforce:communityApp | cyprotex-store.evotec.com | This cookie is used to detect errors on the website - this information is sent to the website's support staff in order to optimize the visitor's experience on the website. | Persistent | IndexedDB |
| li_gc | Stores the user's cookie consent state for the current domain | 180 days | HTTP Cookie | |
| LSKey-c$CookieConsentPolicy | cyprotex-store.evotec.com | Determines whether the user has accepted the cookie consent box. | 1 year | HTTP Cookie |
| PHPSESSID [x3] | EQS Group evotec-compound.mediaporta.de rigenerand-biotech.com | Preserves user session state across page requests. | Session | HTTP Cookie |
| rc::a | HubSpot | This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website. | Persistent | HTML Local Storage |
| rc::b | HubSpot | This cookie is used to distinguish between humans and bots. | Session | HTML Local Storage |
| rc::c | HubSpot | This cookie is used to distinguish between humans and bots. | Session | HTML Local Storage |
| rc::f | HubSpot | This cookie is used to distinguish between humans and bots. | Persistent | HTML Local Storage |
| renderCtx | cyprotex-store.evotec.com | Necessary to facilitate client-side-rendering, which allows the website to place website scripts in the client’s browser. | Session | HTTP Cookie |
| test_cookie | Used to check if the user's browser supports cookies. | 1 day | HTTP Cookie | |
| uncodeAI.css | rigenerand-biotech.com | Determines which device is used by the visitor - This allows the website to adjust to the optimal resolution for that specific device. | Session | HTTP Cookie |
| uncodeAI.images | rigenerand-biotech.com | Determines which device is used by the visitor - This allows the website to adjust to the optimal resolution for that specific device. | Session | HTTP Cookie |
| uncodeAI.screen | rigenerand-biotech.com | Determines which device is used by the visitor - This allows the website to adjust to the optimal resolution for that specific device. | Session | HTTP Cookie |
| wordpress_test_cookie [x2] | laben2.com rigenerand-biotech.com | Used to check if the user's browser supports cookies. | Session | HTTP Cookie |
| wpEmojiSettingsSupports [x3] | belab1407.org belab2122.org laben2.com | This cookie is part of a bundle of cookies which serve the purpose of content delivery and presentation. The cookies keep the correct state of font, blog/picture sliders, color themes and other website settings. | Session | HTML Local Storage |
Preferences (3)
Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
| Name | Provider | Purpose | Maximum Storage Duration | Type |
|---|---|---|---|---|
| CookieConsentBulkSetting-# [x2] | Cookiebot | Enables cookie consent across multiple websites | 1 year | HTML Local Storage |
| lidc | Registers which server-cluster is serving the visitor. This is used in context with load balancing, in order to optimize user experience. | 1 day | HTTP Cookie |
Statistics (35)
Statistic cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
| Name | Provider | Purpose | Maximum Storage Duration | Type |
|---|---|---|---|---|
| __hssc [x2] | HubSpot | Identifies if the cookie data needs to be updated in the visitor's browser. | 1 day | HTTP Cookie |
| __hssrc [x2] | HubSpot | Used to recognise the visitor's browser upon reentry on the website. | Session | HTTP Cookie |
| __hstc [x2] | HubSpot | Sets a unique ID for the session. This allows the website to obtain data on visitor behaviour for statistical purposes. | 180 days | HTTP Cookie |
| _ga [x3] | Registers a unique ID that is used to generate statistical data on how the visitor uses the website. | 2 years | HTTP Cookie | |
| _ga_# [x3] | Used by Google Analytics to collect data on the number of times a user has visited the website as well as dates for the first and most recent visit. | 2 years | HTTP Cookie | |
| _gat [x2] | Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels. | 1 day | HTTP Cookie | |
| _gid [x2] | Registers a unique ID that is used to generate statistical data on how the visitor uses the website. | 1 day | HTTP Cookie | |
| _pk_id# [x8] | Matomo | Collects statistics on the user's visits to the website, such as the number of visits, average time spent on the website and what pages have been read. | 1 year | HTTP Cookie |
| _pk_ref# | Matomo | Used by Piwik Analytics Platform to identify the referring website from which the visitor has come. | 6 months | HTTP Cookie |
| _pk_ses# [x8] | Matomo | Used by Piwik Analytics Platform to track page requests from the visitor during the session. | 1 day | HTTP Cookie |
| hubspotutk [x2] | HubSpot | Sets a unique ID for the session. This allows the website to obtain data on visitor behaviour for statistical purposes. | 180 days | HTTP Cookie |
Marketing (23)
Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
| Name | Provider | Purpose | Maximum Storage Duration | Type |
|---|---|---|---|---|
| #,# | Collects data on user behaviour and interaction in order to optimize the website and make advertisement on the website more relevant. | Persistent | HTML Local Storage | |
| #,#_expiresAt | Collects data on user behaviour and interaction in order to optimize the website and make advertisement on the website more relevant. | Persistent | HTML Local Storage | |
| __ptq.gif | HubSpot | Sends data to the marketing platform Hubspot about the visitor's device and behaviour. Tracks the visitor across devices and marketing channels. | Session | Pixel Tracker |
| __Secure-ROLLOUT_TOKEN | YouTube | Used to track user’s interaction with embedded content. | 180 days | HTTP Cookie |
| __Secure-YEC | YouTube | Stores the user's video player preferences using embedded YouTube video | Session | HTTP Cookie |
| __Secure-YNID | YouTube | Used to track user’s interaction with embedded content. | 180 days | HTTP Cookie |
| _gcl_au | Used by Google AdSense for experimenting with advertisement efficiency across websites using their services. | 3 months | HTTP Cookie | |
| _gcl_ls | Tracks the conversion rate between the user and the advertisement banners on the website - This serves to optimise the relevance of the advertisements on the website. | Persistent | HTML Local Storage | |
| GlobalValueProviders__MUTEX_X | cyprotex-store.evotec.com | Used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences. | Persistent | HTML Local Storage |
| LAST_RESULT_ENTRY_KEY [x2] | YouTube | Used to track user’s interaction with embedded content. | Session | HTTP Cookie |
| LogsDatabaseV2:V#|LogsRequestsStore | YouTube | Used to track user’s interaction with embedded content. | Persistent | IndexedDB |
| pagead/1p-user-list/# | Tracks if the user has shown interest in specific products or events across multiple websites and detects how the user navigates between sites. This is used for measurement of advertisement efforts and facilitates payment of referral-fees between websites. | Session | Pixel Tracker | |
| pctrk | cyprotex-store.evotec.com | Tracks the individual sessions on the website, allowing the website to compile statistical data from multiple visits. This data can also be used to create leads for marketing purposes. | 1 year | HTTP Cookie |
| TESTCOOKIESENABLED [x2] | YouTube | Used to track user’s interaction with embedded content. | 1 day | HTTP Cookie |
| VISITOR_INFO1_LIVE | YouTube | Tries to estimate the users' bandwidth on pages with integrated YouTube videos. | 180 days | HTTP Cookie |
| YSC | YouTube | Registers a unique ID to keep statistics of what videos from YouTube the user has seen. | Session | HTTP Cookie |
| yt-icons-last-purged [x2] | YouTube | Necessary for the implementation and functionality of YouTube video-content on the website. | Persistent | HTML Local Storage |
| ytidb::LAST_RESULT_ENTRY_KEY | YouTube | Used to track user’s interaction with embedded content. | Persistent | HTML Local Storage |
| YtIdbMeta#databases [x2] | YouTube | Used to track user’s interaction with embedded content. | Persistent | IndexedDB |
Unclassified (5)
Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
| Name | Provider | Purpose | Maximum Storage Duration | Type |
|---|---|---|---|---|
| ##communityApp ~ #/s ~ # | cyprotex-store.evotec.com | Pending | Persistent | IndexedDB |
| chatbase_anon_id | www.chatbase.co | Pending | Session | HTTP Cookie |
| gatesUnlocked | www.evotec.com | Pending | Persistent | HTML Local Storage |
| message_bubbles_have_been_shown | www.chatbase.co | Pending | Session | HTML Local Storage |
| yt-player-caption-persistence | YouTube | Pending | Persistent | HTML Local Storage |
Financial Publications - Evotec
-
-
-
Solutions
-
Company
-
IR & News
back
-
-
…
-
Publications

Publications
================
Publications
Publications
In this publications section you can find the Company’s Annual Reports, Quarterly Reports/Statements, our Sustainability Report as well as non-financial statements. Furthermore, there are available presentations held at Investor Relations events and analyst calls.
SEC Filings
On this page you can also find all documents published in relation to our public listing on NASDAQ.
For the original documents published on the EDGAR ("Electronic Data Gathering, Analysis, and Retrieval") database of the U.S. Securities and exchange commission ("SEC"), please use the below link.
Three shareholders, Novo Holdings A/S, T. Rowe Price Group Inc. and Mubadala Investment Company, currently hold more than 5% of the shares of Evotec SE. The free float according to the definition of the Frankfurt Stock Exchange is approx. 72% according to our estimates (Evotec: 09/2023).
Financial & Sustainability Reports
Please find below Evotec's financial reports and sustainability reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations.
An overview of all published sustainability-related reports can also be found in the ESG Performance section .
Current year - 2026
2025
2024
2023
-
Evotec’s Contribution to UN Sustainable Development Goals 2023, PDF
-
Webcast Analyst Call Business Update Q2/6M 2023 (28 July 2023)
2022
Annual Report
Sustainability Report
Financial Statements
Preliminary FY 2022 Results
Interim Statement 9M 2022
Half-year Report 2022
Interim Statement Q1 2022
2021
Annual Report
Sustainability Report
Financial Statements
Interim Statement 9M
Half-year Report
Interim Statement Q1
2020
Annual Report
Sustainability Report
Financial Statements
Quarterly Statement 9M
Half-year Report
Quarterly Statement Q1
2019
Annual Report
Financial Statements
Separate Non-financial Group Report
Quarterly Statement 9M
Half-year Report
Webcast / Conference Call Regarding the Acquisition of Just.Bio
Quarterly Statement Q1
2018
Annual Report
Financial Statements
Separate Non-financial Group Report
Quarterly Statement 9M
Half-year Report
Quarterly Statement Q1
2017
Annual Report
Financial Statements
Separate Non-financial Group Report
Webcast / Conference Call Regarding the Fiscal Year 2017 Results
**
Quarterly Statement 9M**
Half-year Report
Conference Call / Webcast Regarding the Acquisition of Aptuit
Quarterly Statement Q1
2016
Annual Report
Financial Statements
Conference Call / Webcast Regarding Strategic Collaboration with Celgene
Quarterly Statement Q3
Conference Call / Webcast Regarding the Offer to Acquire Cyprotex
Half-year Report
Quarterly Statement Q1
2015
Annual Report
Financial Statements
Nine-month Interim Report
Half-year Report
First Quarter Report
2014
Annual Report
Financial Statements
Conference Call / Webcast Announcing Negotiations on Major Collaboration with Sanofi
Nine-month Interim Report
Half-year Report
First Quarter Report
2013
Annual Report
Financial Statements
Nine-month Interim Report
Half-year Report
First Quarter Report
2012
Annual Report
Financial Statements
Half-year Report
First Quarter Report
2011
Annual Report
Financial Statements
Third Quarter Report
Conference Call / Webcast Announcing License Agreement with Roche
Half Year Report
Conference Call and Webcast Announcing the Acquisition of Compound Focus, Inc.
First Quarter Report
Conference Call and Webcast Announcing the Acquisition of Kinaxo
2010
Annual Report
Financial Statements
Conference Call and Webcast Announcing the Alliance With MedImmune
Third Quarter Report
Half Year Report
Conference Call and Webcast Announcing the Acquisition of DeveloGen
First Quarter Report
2009
Annual Report
Financial Statements
Third Quarter Report
Half Year Report
First Quarter Report
2008
Annual Report
Financial Statements
Third Quarter Report
Half Year Report
First Quarter Report
2007
Annual Report
Financial Statements
Third Quarter Report
Half Year Report
First Quarter Report
2006
Annual Report
Financial Statements According to HGB
Third Quarter Report
Second Quarter Report
First Quarter Report
2005
Annual Report
Third Quarter Report
Second Quarter Report
First Quarter Report
New Segmental P&L Statements
2004
Annual Report
Third Quarter Report
Second Quarter Report
First Quarter Report
2003
Annual Report
Third Quarter Report
Second Quarter Report
First Quarter Report
2002
Annual Report
Third Quarter Report
Second Quarter Report
First Quarter Report
2001
Annual Report
Third Quarter Report
Second Quarter Report
First Quarter Report
2000
Annual Report
Third Quarter Report
Second Quarter Report
First Quarter Report
Oxford Asymmetry International plc 2000 Interim Statement
1999
Annual Report
Third Quarter Report
Oxford Asymmetry International plc Annual Report 1999
IR & ESG Presentations
Company Presentaton
![]()
Downlaods 2023
-
Vorstandspräsentation Hauptversammlung 2023, 20. Juni 2023 5.092 MB
-
Analyst Call Business Update First Half-year 2023 (20 July 2023) 847.14 KB
![]()
Presentations 2024
Presentations 2023
-
Präsentation Analyst Call Preliminary Results 2022, 28 March 2023
-
Management Presentation Annual General Meeting 2023, 20 June 2023 (in German)
-
Presentation Analyst Call Business Update H1 2023, 28 July 2023
Former Presentations
Aug 13, 2026, Hamburg, Germany
Evotec Announces Second Quarter and First Half 2026 Results: Growing Commercial Momentum
=============================================================================================
- H1 2026 financial performance: Q2 and H1 Group revenues of €143.5 m and €300.1 m, respectively (Q2: €146.3 m, H1: €313.2 m at CER); adj. Group EBITDA of -€20.8 m and -€42.7 m, respectively (Q2: -€18.6 m, H1: -€37.4 m at CER)
- Updated FY 2026 outlook: Expected Group revenues of €570 to €610 m (€595 to 635 m CER) and adj. Group EBITDA of -€70 to -€105 m (-€60 to -€90 m CER), compared with previous guidance of €700 to €780 m (€730 to €810 m CER) for Group revenues and €0 to €40 m (€10 to €50 m CER) for adj. Group EBITDA
- Commercial momentum across segments: Net sales* in D&PD ex-strategic partnerships increased by approximately 28% year-on-year in H1 2026, reflecting improved customer engagement and commercial execution; Just – Evotec Biologics continued to benefit from high capacity utilization and expansion of its customer base
- Horizon execution on track: Transformation progressing as planned across operational excellence, scientific leadership and commercial execution; early cost savings delivered in H1 support confidence in achieving 2026 savings contribution; 2026 contribution of approximately 20-30% of previously announced €75 million annual run-rate savings target by the end of 2027
- Governance Update: Camilla Macapili Languille stepped down from Evotec’s Supervisory Board
- Additional information available: As final Q2/H1 2026 results are consistent with preliminary results and updated FY 2026 outlook communicated on July 14, 2026, Evotec will not host a separate webcast in conjunction with its final results reporting. The replay, presentation slides and transcript from the July 14 webcast remain available under this link .
Hamburg, Germany, August 13, 2026 - Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced financial results for the second quarter and first half of 2026 and confirmed its updated full-year 2026 outlook.
Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:
“While the first half of 2026 results reflect the challenging start to the year previously anticipated, we are seeing clear and encouraging signs that our actions are gaining traction. Commercial activity is improving across both segments, with strong growth in D&PD base net sales, increasing customer engagement and continued momentum at Just – Evotec Biologics. At the same time, Horizon is progressing according to plan, supporting greater focus, accountability and efficiency across the organization. While the financial benefits of these developments will take time to fully materialize, they represent important building blocks for recovery and the next phase of growth. We continue to see attractive opportunities across both segments and remain confident in the strength of our strategic partnership pipeline, with a significant portion of opportunities progressing through advanced discussions. Our continued investment in next-generation discovery capabilities, including our proteomics and transcriptomics platforms, strengthens our scientific differentiation, enhances the quality of our partner offerings and expands future opportunities for strategic collaborations.”
Selected Business Highlights
Strategic Partnership Pipeline
Evotec maintains an active strategic partnership opportunity pipeline, supported by ongoing discussions across a broad range of therapeutic areas and modalities. The Company is actively advancing opportunities at various stages of evaluation, including a significant number in advanced due diligence and term sheet discussions. While Evotec remains confident in its ability to enter new strategic partnerships in 2026, the timing, complexity and revenue ramp-up associated with individual agreements remain inherently variable and are reflected in the Company's updated full-year 2026 outlook.
As communicated in the outlook update on July 14, 2026 , Evotec expects lower contributions from both existing and potential new strategic partnerships in 2026 than previously anticipated. Approximately 40% of the reduction in expected full-year 2026 revenue relative to the previous outlook reflects revised project phasing and milestone schedules for existing partnerships, with the associated revenues now expected to be recognized in 2027. Approximately 45% reflects lower-than-anticipated contributions from potential new strategic partnerships due to the timing of agreement execution and development activities. Approximately 15% is attributable to lower-than-expected revenue conversion against the Company’s internal ambition for accelerated sales-to-revenue conversion, with the associated revenues now also expected to shift into 2027.
Commercial Execution
Commercial execution remains a key focus area of the Horizon transformation and an important driver of Evotec's path to recovery. Within the Horizon transformation, the Company has strengthened its commercial organization, sharpened customer focus and enhanced business development processes across both segments. These efforts are increasingly reflected in commercial indicators, including higher customer engagement, growing new business activity and improved sales effectiveness.
Commercial momentum across Evotec’s base CRO and CDMO businesses strengthened during the first half of 2026. In Drug Discovery & Preclinical Development (D&PD), net sales increased by more than 28% year-on-year, reflecting improved customer engagement and commercial execution. Just – Evotec Biologics continues to demonstrate positive operating momentum as well, supported by high-capacity utilization and expansion of its customer base.
Based on the typical conversion cycle between sales generation and revenue recognition, increased commercial activity in D&PD is expected to contribute increasingly to revenues from the fourth quarter of 2026 onwards.
Governance Update: Supervisory Board Transition
Camilla Macapili Languille has decided to step down from Evotec's Supervisory Board effective August 7, 2026. Since her appointment in June 2022, she has served as an independent Supervisory Board member and as a member of the Audit & Compliance Committee. Following her departure, Supervisory Board member Wes Wheeler has been appointed by the Supervisory Board to the Audit & Compliance Committee. Evotec would like to thank Ms. Macapili Languille for her commitment and service.
The Supervisory Board has initiated the process to identify a successor and will focus on candidates with strong financial expertise to maintain the Supervisory Board's balanced competency profile and committee composition.
Strategic Evaluation
The strategic evaluation announced in connection with the Company's first quarter 2026 results on May 6, 2026, remains ongoing and continues alongside the implementation of the Horizon transformation program. Additional details regarding the review are available in the Company's Q1 2026 results announcement.
Horizon Transformation
Horizon remains Evotec's framework for the next phase of its transformation, focused on operational excellence, scientific leadership and commercial execution.
Since the launch of Horizon in March 2026 , Evotec has continued to advance measures to streamline operations, increase agility and focus resources on areas with the clearest path to value. The updated full-year 2026 outlook does not change the strategic direction of Horizon or the timeline for its implementation.
Evotec remains on track to deliver approximately 20-30% of cost savings in 2026 as part of its previously announced objective of €75 million in annual run-rate savings by the end of 2027. Horizon measures implemented to date are delivering as planned, with first-half savings providing a foundation for achieving the expected 2026 savings contribution.
Financial Results
Claire Hinshelwood, Chief Financial Officer of Evotec, said:
“As previously announced, we confirm that our updated full-year outlook primarily reflects a revised view surrounding strategic partnership activities and milestone contributions in the second half of the year. The reduced contribution from these activities is expected to affect profitability disproportionately relative to revenues, reflecting their typically attractive economics and impact on overall capacity utilization. The current year continues to require disciplined execution and careful cash flow management. We remain focused on driving efficiency across the organization, increasing transparency around our business performance and strategic priorities and delivering on our Horizon objectives. Alongside ongoing cost and footprint optimization, we continue to invest in key strategic areas to support future growth opportunities while preserving financial flexibility.”
Group Financials
For the second quarter of 2026, Group revenues amounted to €143.5 million (€146.3 million CER) compared to €171.2 million in the same period in 2025, representing a 16.2% decrease. Adjusted Group EBITDA was -€20.8 million (-€18.6 million CER), reflecting a decrease of 320.3% versus -€5.0 million in the same prior‑year period, mainly driven by lower revenues.
For the six months ended June 30, 2026, Evotec generated Group revenues of €300.1 million (€313.2 million CER), a 19.2% decline versus €371.2 million in the first half of 2025. R&D expenses were managed in line with the Company’s focus on cost discipline, decreasing to €20.3 million (6.8% of total Group revenues) compared to €29.4 million in the prior year (7.9% of total Group revenues). Adjusted Group EBITDA decreased to -€42.7 million (-€37.4 million CER), down from -€1.9 million for H1 2025. The decrease was partially offset by lower cost of revenue as well as reduced R&D and SG&A expenses.
Evotec closed the second quarter of 2026 with a liquidity position of €465.6 million, reflecting a net cash position.
Segment Financials
Discovery and Preclinical Development (D&PD)
For the second quarter of 2026, revenues for Discovery & Preclinical Development amounted to €108.1 million (€109.5 million CER), representing a year-on-year decrease of 15.8%. Adjusted EBITDA for the quarter amounted to -€14.6 million (-€13.0 million CER), down from -€2.5 million in the second quarter of 2025.
For the first half of 2026, revenues totaled €228.1 million (€235.9 million CER), representing a year-on-year decrease of 15.3% compared with €269.0 million in the prior-year period, primarily driven by weak sales to revenue conversion across all business areas and softer-than-expected customer demand, reflecting the continued challenging market environment. Adjusted EBITDA for the segment was -€24.4 million (-€18.4 million CER), compared with -€9.3 million in the prior year, reflecting the reduced topline performance.
Just – Evotec Biologics (JEB)
For the second quarter of 2026, revenues for Just – Evotec Biologics amounted to €35.4 million (€36.8 million CER), representing a year-on-year decrease of 17.4%. Adjusted EBITDA reached -€6.2 million (-€5.6 million CER), down from -€2.5 million in the prior-year period.
For the first half of 2026, revenues totaled €72.3 million (€77.3 million CER), representing a year-on-year decrease of 29.3% from €102.2 million in the same period in 2025. The decline was mainly driven by the non-repeat of the Sandoz license sale in Q1 2025. Adjusted EBITDA amounted to -€18.2 million (-€19.0 million CER), down from €7.5 million in the same period in 2025 based on the Sandoz license sale in Q1 2025.
Re-affirming Full-year 2026 Guidance
As announced on July 14, 2026, Evotec confirms its full-year 2026 outlook for Group revenues of approximately €570 to €610 million (€595 to €635 million CER) and adjusted Group EBITDA of approximately -€70 to -€105 million (-€60 to -€90 million CER). In light of the updated 2026 outlook, Evotec is in the process of reviewing its mid-term framework.
Additional Information
Evotec hosted a webcast and conference call on Tuesday, July 14, 2026. An on-demand replay of the webcast as well as the presentation slides and transcript are available under this link .
Downloads
![]()
About Evotec SE
Evotec is a life science company pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, Evotec accelerates the journey from concept to cure with greater speed, intelligence and precision. The company's expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms including Molecular Patient Databases, PanOmics and induced pluripotent stem cell-based disease modelling. Through flexible partnering models tailored to customers' needs, Evotec works with all Top 20 pharmaceutical companies, more than 800 biotechnology companies, academic institutions and other healthcare stakeholders. Evotec's offerings range from standalone services to fully integrated research and development programmes and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, the company is redefining biologics development and manufacturing to improve accessibility and affordability. With a portfolio of more than 100 proprietary research and development assets, most of which are co-owned, Evotec focuses on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology and immunology. Evotec's global team of around 4,500 experts operates from sites in Europe and the United States, providing complementary technologies and services through a network of synergistic centres of excellence. Learn more at www.evotec.com and follow Evotec on LinkedIn and X at @Evotec .
Forward-Looking Statements
This announcement contains forward-looking statements concerning future events, including Evotec's preliminary financial results, updated full-year 2026 outlook, expected commercial conversion, anticipated strategic partnership and milestone contributions, Horizon implementation, expected cost savings, liquidity, financial flexibility and future business performance.Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of these words and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on information available to Evotec and on expectations and assumptions considered reasonable by the company at the time the statements were made. No assurance can be given that these expectations will prove correct. Forward-looking statements involve known and unknown risks and are based on assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond Evotec's control. Evotec expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement to reflect changes in expectations, events, conditions or circumstances, except as required by applicable law.
Contact Us
+49 40 560 81 0
Follow Us
©2026, All rights reserved.
Aug 6, 2026, Hamburg, Germany
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
==============================================================================================================
- Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey’s discovery-stage programs
- Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need
Hamburg, Germany, August 6, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics, Inc. (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.
Under the agreement, Odyssey will leverage Evotec's integrated data-driven discovery platform, advanced screening capabilities and AI-enabled data science technologies to discover and validate differentiated small molecule drug candidates across multiple high-value disease targets. By combining high-throughput experimentation with machine learning-driven analysis, the collaboration is designed to accelerate the identification of validated hit series and enable the rapid progression of promising therapeutic programs with the potential to transform the standard of care.
The collaboration combines Odyssey’s deep expertise in autoimmune and inflammatory disease biology with Evotec’s industry-leading discovery infrastructure and proprietary compound libraries. By bringing together complementary scientific and technological strengths, the companies aim to accelerate early-stage research and efficiently generate and advance new medicines.
Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said:
“Drug discovery increasingly depends on the ability to integrate deep disease biology with advanced experimental and computational approaches to drug discovery. This collaboration with Odyssey illustrates well Evotec’s strategy in applying integrated discovery platform technologies to complex disease areas where new approaches are urgently needed. Together, we aim to generate differentiated and validated starting points for Odyssey to develop into new therapies for autoimmune and inflammatory diseases.”
Evotec is eligible to receive milestone payments based on the successful delivery of validated hit series for each target, aligning value creation with successful discovery outcomes. Detailed financials were not disclosed.
Downloads
![]()
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of more than 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec .
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact Us
+49 40 560 81 0
Follow Us
©2026, All rights reserved.
Aug 3, 2026, Los Angeles, CA, USA
Third-Party PR: Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
==================================================================================================================================
- Collaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Bioscience’s lead investigational candidate for rare pediatric diseases
- Evotec brings deep drug development expertise, serving leading pharmaceutical and biotechnology companies across the life sciences industry
LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168. The work will be conducted in collaboration with NAD Pharmaceuticals Corp. , Niagen Bioscience’s wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases.
Under the collaboration, Evotec will conduct pharmacokinetic and pharmacodynamic studies and validate bioanalytical methods to further characterize NB4168 and support Niagen Bioscience’s preclinical and Investigational New Drug (IND)-enabling development activities. NB4168 is Niagen Bioscience’s proprietary oral small-molecule candidate initially developed for Ataxia Telangiectasia (A-T), a rare pediatric genetic disease with no approved treatments.
The studies will take place at Evotec’s state-of-the-art campus in Verona, Italy, which provides a streamlined path to the clinic through Evotec’s INDiGO platform. It integrates the ICH-directed activities required for early-phase clinical evaluation—including active pharmaceutical ingredient development, drug product development, safety, absorption, distribution, metabolism, and excretion, and regulatory and clinical services. This vertically integrated model is designed to accelerate timelines, reduce development risk and improve cost efficiency.
“Selecting Evotec adds streamlined drug development capabilities and executional scale to the NB4168 program,” said Ozan Pamir, Chief Financial Officer of Niagen Bioscience. “This collaboration is an important step in building the pharmacological and bioanalytical evidence required to advance NB4168 toward clinical evaluation in patients with A-T.”
In nonclinical pharmacokinetic studies conducted to date, NB4168 has demonstrated substantially higher blood exposure compared with NR chloride, supporting its continued development as a more bioavailable pharmaceutical candidate. Existing NR research in A-T, including two independent open-label clinical studies and several preclinical studies of NR chloride, reported improvements in neurological measures and related biomarkers (Presterud et al., 2023 ; Veenhuis et al., 2021 ; Yang et al., 2021 ; Fang et al., 2016 ).
“Our collaboration with Niagen Bioscience demonstrates the value of Evotec’s integrated development offering in supporting innovative companies as they advance assets toward the clinic,” said Dr. Ashiq Khan, EVP, Chief Commercial Officer of Evotec. “NB4168 is a promising program, supported by a defined biological rationale and a focused preclinical development plan. We look forward to helping generate the data needed to inform the next stage of development for this investigational candidate.”
About NB4168
NB4168 is a distinct, proprietary small molecule designed for oral pharmaceutical development. It is not commercially available as a supplement or approved drug and is protected by Niagen Bioscience’s patent portfolio, including a composition-of-matter patent. After oral administration, NB4168 is designed to deliver significantly increased exposure to NR, which enters cells directly and is converted through the nicotinamide riboside kinase (NRK) pathway into NAD+. NAD+ supports biological processes including DNA repair, mitochondrial function, cellular energy production and stress responses—pathways that are disrupted in A-T.
Niagen Bioscience has received U.S. Food and Drug Administration Rare Pediatric Disease Designation and European Medicines Agency Orphan Medicinal Product Designation for NB4168 for the treatment of A-T. The Company is advancing preclinical development activities and plans to submit an IND application to the FDA in anticipation of initiating human clinical studies.
About Ataxia Telangiectasia (A-T)
A-T is a rare genetic disease caused by mutations in the ATM gene. The disease typically presents in early childhood and is characterized by progressive loss of motor coordination, impaired immune function, increased susceptibility to infections, pulmonary complications, and a substantially elevated risk of cancer. Children living with A-T often experience worsening neurological disability over time, with many requiring wheelchair assistance as the disease progresses. There are currently no FDA-approved therapies for A-T, and treatment is largely limited to supportive care. A-T impacts roughly 1 in 40,000 people in the U.S. (Riboldi et al., 2023 ; Teive et al., 2015 ) and 1 in 150,000 people in Europe (Bhatt et al., 2015 ).
For additional information on Niagen Bioscience’s pharmaceutical program and NB4168, visit www.niagenbioscience.com/nad-pharmaceuticals .
-
-
-
Solutions
-
Company
-
IR & News
back
-
-
…
-
Annual General Meeting Archive

Annual General Meeting Archive
Annual General Meeting Archive
Recording of the Management Speech
Convocation Documents for Download
Webcast of the Annual General Meeting
Convocation Documents for Download
Ordinary (Virtual) Annual General Meeting 2023
Ordinary (Virtual) Annual General Meeting 2022
Ordinary (Virtual) Annual General Meeting 2021
Annual General Meeting Archive
Annual General Meeting Archive
Recording of the Management Speech
Convocation Documents for Download
Webcast of the Annual General Meeting
Convocation Documents for Download
Ordinary (Virtual) Annual General Meeting 2023
Ordinary (Virtual) Annual General Meeting 2022
Ordinary (Virtual) Annual General Meeting 2021
Annual General Meeting Archive
Recording of the Management Speech
Convocation Documents for Download
Webcast of the Annual General Meeting
Convocation Documents for Download
Ordinary (Virtual) Annual General Meeting 2023
Ordinary (Virtual) Annual General Meeting 2022
Ordinary (Virtual) Annual General Meeting 2021
Annual General Meeting Archive
Annual General Meeting Archive
Recording of the Management Speech
Convocation Documents for Download
Webcast of the Annual General Meeting
Convocation Documents for Download
Ordinary (Virtual) Annual General Meeting 2023
Ordinary (Virtual) Annual General Meeting 2022
Ordinary (Virtual) Annual General Meeting 2021
Please see below information regarding Annual General Meetings of previous years.
Ordinary Annual General Meeting 2025
The Annual General Meeting of Evotec SE was held on Tuesday, 3 June 2025, at 10.00 a.m. (CEST), at CinemaxX Hamburg-Dammtor, Room 1, Dammtordamm 1, 20354 Hamburg, Germany as an in-person event.
If you wish to view our Annual General Meeting archive you can do so here .
Agenda
- Presentation of the approved annual financial statements and the consolidated financial statements of Evotec SE as of 31 December 2024, as approved by the Supervisory Board, the management reports for Evotec SE and the Group for the financial year 2024, the report of the Supervisory Board for the financial year 2024 and the comments by the Management Board regarding this information pursuant to Sections 289a, 315a of the German Commercial Code (Handelsgesetzbuch, HGB).
- Resolution discharging the members of the Management Board of liability for financial year 2024.**
2.1** Dr Christian Wojczewski
2.2 Aurélie Dalbiez**
2.3** Dr Cord Dohrmann
2.4. Dr Matthias Evers**
2.5** Laetitia Rouxel
2.6 Dr Craig Johnstone**
2.7** Dr Werner Lanthaler - Resolution discharging the members of the Supervisory Board of liability for financial year 2024.
- Resolution regarding the election of the auditor of the consolidated financial statements and the auditor of the sustainability report for financial year 2025 and of the auditor for any review of additional financial information during the year4.1 Election of the auditor of the the consolidated financial statements and of the auditor for any review of additional financial information during the year**
4.2** Election of the auditor of the sustainability report for financial year 2025 - Resolution to approve the Remuneration Report 2024
- Resolution on amending the Articles of Association to renew the option of holding virtual general meetings
- Resolution on modifying the Share Performance Plan 2022 (modification of the authorisation to issue subscription rights to Management Board members of Evotec SE, members of management boards of affiliated companies in Germany and abroad and selected managers of Evotec SE and affiliated companies in Germany and abroad as part of a Share Performance Plan 2022; modification of the contingent capital available to satisfy subscription rights issued and exercised on the basis of this authorisation; amendment of the Articles of Association) and approval of the remuneration system for the Executive Board members.7.1 Replacement of the performance target “Revenue growth” by “Growth in adjusted Group EBITDA” in the Share Performance Plan 2022**
7.2** Modification of the issue period for Share Performance Awards in the Share Performance Plan 2022 when Management Board members join in the course of the year**
7.3** Modification of contingent capital
7.4. Amendment to Article 5 (7) of the Articles of Association
7.5. Approval of the remuneration system for Management Board members
Downloads
![]()
Recording of the Management Speech
Please find below the recording of the Management Speech at the Annual General Meeting 2025.
Youtube video consent fallback text.
If you cannot view the recording above, please watch the Annual General Meeting here .
Convocation Documents for Download
-
Corporate governance declaration for the 2024 financial year, PDF
-
Modified remuneration system for members of the Management Board (agenda item 7), PDF
-
Presentation Corporate Governance Roadshow, January 2025, PDF
-
Total number of shares and voting rights at the time of convening the Annual General Meeting, PDF
Proxy Voting
Further Downloads
Countermotions
There were no countermotions.
Confirmation of the vote count pursuant to section 129 (5) sentence 1 AktG:
Pursuant to section 129 (5) sentence 1 of the German Stock Corporation Act (AktG), the person voting may request confirmation from the company within one month of the day of the Annual General Meeting as to whether and how his or her vote was counted. A request to this effect may be sent by e-mail to: [email protected]
Hotline
Monday to Friday from 9 am to 5 pm by phone on +49 (0)89 8896906 610
Jul 23, 2026, Palo Alto, CA, USA
Third-Party PR: Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management
=================================================================================================
- Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting
PALO ALTO, Calif.-- July 23, 2026-- Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), the global drug discovery and development company, has selected Navan to manage its complete corporate Travel and Expense (T&E) program in its top global markets.
A life science company that is pioneering the future of drug discovery and development, Evotec had historically managed T&E independently across different countries, meaning employees were dealing with a patchwork of different tools and manual offline processes. As part of its focus on operational excellence, Evotec is further streamlining these processes through one unified, easy-to-use platform that supports consistency, transparency, and efficiency.
“Simplifying processes and strengthening operational excellence while enabling our employees with efficient tools are key priorities for Evotec,” said Kay Prätorius, VP Procurement at Evotec. “Transitioning to the single, intuitive Navan platform will enhance the overall user experience, providing real-time visibility and control over our global travel and expense activities.”
Evotec is rolling out Navan across Germany, the UK, U.S., Italy, and France, aiming to streamline user experience and reduce the need for manual entry by automating reconciliation directly from the point of swipe.
“We often see significant efficiency gains when organizations upgrade and modernize their travel and expense systems,” said Zahir Abdelouhab, SVP, Enterprise Sales, EMEA at Navan. “Evotec is taking an important step in further streamlining and standardizing its processes and Navan is supporting this by bringing greater clarity and simplicity to travel and expense management, supporting teams in focusing on their core work.”
· Preliminary H1 2026 results: Group revenues of approximately €300.1 million and adjusted Group EBITDA of approximately -€42.7 million; full H1 2026 financial results to be published on August 13, 2026, as scheduled
· Updated FY 2026 outlook: Group revenues now expected to be approximately €570 to 610 million (€595 to 635 million CER) and adjusted Group EBITDA approximately -€70 to -105 million (-€60 to -90 million CER), compared with previous guidance of €700-780 million (€730-810 million CER) for Group revenues and €0-40 million (€10-50 million CER) for adjusted Group EBITDA
· Key drivers of the updated outlook: Approximately ~40% of the revenue difference shifted to 2027 primarily due to revised phasing and milestone schedules in existing partnerships; ~45% shifted beyond Q4 2026 due to delays in strategic partnerships under negotiation; ~15% attributable to lower-than-expected sales to revenue conversion relative to previously issued guidance
· Positive base business momentum: Net sales in D&PD ex-strategic partnerships increased by approximately 28% year-on-year in H1 2026, reflecting improved customer engagement and commercial execution; Just – Evotec Biologics continued
Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Hamburg, Germany – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for the second quarter and first half of 2026 and updated its full-year 2026 outlook. Full financial results for the second quarter and first half of 2026 will be published on August 13, 2026, as scheduled.
Based on preliminary figures, Evotec expects Group revenues for the first half of 2026 of approximately €300.1 million and adjusted Group EBITDA of approximately -€42.7 million. As of June 30, 2026, liquidity is expected to amount to approximately €465.6 million.
Reflecting these factors, Evotec now expects full-year 2026 Group revenues of approximately €570 to 610 million (€595 to 635 million CER) and adjusted Group EBITDA of approximately -€70 to -105 million (-€60 to -90 million CER). This compares with previous guidance of €700-780 million (€730-810 million CER) for Group revenues and €0-40 million (€10-50 million CER) for adjusted Group EBITDA.
– End of the ad hoc release –
-
-
-
Solutions
-
Company
-
IR & News
back
-
-
…
-
Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Hamburg, Germany – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for the second quarter and first half of 2026 and updated its full-year 2026 outlook. Full financial results for the second quarter and first half of 2026 will be published on August 13, 2026, as scheduled.
Based on preliminary figures, Evotec expects Group revenues for the first half of 2026 of approximately €300.1 million and adjusted Group EBITDA of approximately -€42.7 million. As of June 30, 2026, liquidity is expected to amount to approximately €465.6 million.
Reflecting these factors, Evotec now expects full-year 2026 Group revenues of approximately €570 to 610 million (€595 to 635 million CER) and adjusted Group EBITDA of approximately -€70 to -105 million (-€60 to -90 million CER). This compares with previous guidance of €700 to 780 million (€730 to 810 million CER) for Group revenues and €0 to 40 million (€10 to 50 million CER) for adjusted Group EBITDA.
Contact Us
+49 40 560 81 0
Follow Us
©2026, All rights reserved.
-
-
-
Solutions
-
Company
-
IR & News
back
-
-
…
-
Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
-
Preliminary H1 2026 results: Group revenues of approximately €300.1 million and adjusted Group EBITDA of approximately -€42.7 million; full H1 2026 financial results to be published on August 13, 2026, as scheduled
-
Updated FY 2026 outlook: Group revenues now expected to be approximately €570 to 610 million (€595 to 635 million CER) and adjusted Group EBITDA approximately -€70 to -105 million (-€60 to -90 million CER), compared with previous guidance of €700-780 million (€730-810 million CER) for Group revenues and €0-40 million (€10-50 million CER) for adjusted Group EBITDA
-
Key drivers of the updated outlook: Approximately ~40% of the revenue difference shifted to 2027 primarily due to revised phasing and milestone schedules in existing partnerships; ~45% shifted beyond Q4 2026 due to delays in strategic partnerships under negotiation; ~15% attributable to lower-than-expected sales to revenue conversion relative to previously issued guidance
-
Positive base business momentum: Net sales in D&PD ex-strategic partnerships increased by approximately 28% year-on-year in H1 2026, reflecting improved customer engagement and commercial execution; Just – Evotec Biologics continued to benefit from high capacity utilization and expansion of its customer base
-
Horizon execution on track: Transformation progressing as planned across operational excellence, scientific leadership and commercial execution; Evotec remains on track to deliver approximately 20-30% of cost savings in 2026 as part of its previously announced target of €75 million in annual run-rate savings by the end of 2027
-
Investor and analyst webcast and conference call: July 14, 2026, at 2:00 p.m. CEST / 1:00 p.m. BST / 8:00 a.m. EDT; details can be found below or under this link
Hamburg, Germany, July 13, 2026 - Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for the second quarter and first half of 2026 and updated its full-year 2026 outlook. Full financial results for the second quarter and first half of 2026 will be published on August 13, 2026, as scheduled.
Based on preliminary figures, Evotec expects Group revenues for the first half of 2026 of approximately €300.1 million and adjusted Group EBITDA of approximately -€42.7 million. As of June 30, 2026, liquidity is expected to amount to approximately €465.6 million.
Looking ahead to the second half of 2026, Evotec now expects lower contributions than previously anticipated in the period from both existing and potential new strategic partnerships that are currently under discussion. Approximately 40% of the revenue gap relative to the previous outlook primarily reflects revised phasing and milestone schedules for existing partnerships, with the associated revenues now expected to be recognized in 2027. Approximately 45% reflects lower-than-anticipated contributions from potential new strategic partnerships due to the timing of agreement execution and development activities. Approximately 15% of the revenue gap is attributable to lower-than-expected revenue conversion.
At the same time, sales momentum in the base CRO and CDMO business has strengthened in the first half of 2026 compared with the first half of 2025, across both the D&PD and Just – Evotec Biologics segments. Just – Evotec Biologics continues to demonstrate positive operating momentum, supported by high capacity utilization and expansion of its customer base. D&PD net sales increased by more than 28% year-on-year, reflecting improved customer engagement and commercial execution. The increased commercial activity in D&PD is expected to translate into revenues from Q4 2026 onwards.
Reflecting these factors, Evotec now expects full-year 2026 Group revenues of approximately €570 to 610 million (€595 to 635 million CER) and adjusted Group EBITDA of approximately -€70 to -105 million (-€60 to -90 million CER). This compares with previous guidance of €700-780 million (€730-810 million CER) for Group revenues and €0-40 million (€10-50 million CER) for adjusted Group EBITDA.
Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:
“As expected, our preliminary H1 results reflect a challenging start to the year. However, we are also seeing trends indicating that the changes we've implemented are beginning to take hold. We're seeing growing momentum build across our base CRO and CDMO businesses with strong D&PD net sales growth, customer engagement rising, and sustained progress at Just – Evotec Biologics. Furthermore, Horizon cost streamlining is well on track. These are the metrics we control, and they're moving in the right direction. At the same time, we're updating our full-year outlook to reflect two factors: lower anticipated near-term contributions from new strategic partnerships and timing delays on certain milestone-related revenues from existing partnerships. This is a revision of timing, not of conviction. Our confidence in the long-term value of our partnered pipeline remains fully intact. In fact, that pipeline is more active than ever. We're in advanced discussions with several well-established partners on programs addressing real unmet medical need across renal disease, oncology, women's health, obesity, and beyond. This new foundation we're building today is what will drive the next phase of growth at Evotec.”
Claire Hinshelwood, Chief Financial Officer of Evotec, said:
“Our new outlook reflects primarily an updated view on strategic partnership activities and milestone contributions in the second half of this year. As these revenues typically carry a higher margin profile, the impact on adjusted EBITDA is expected to be disproportionate. In response, we remain focused on disciplined cash management, optimizing our cost base and reviewing our footprint capacity while continuing to invest in our strategic priorities.”
Preliminary Segment Results (unaudited)
Discovery & Preclinical Development (D&PD)
For the second quarter of 2026, preliminary unaudited revenues for Discovery & Preclinical Development are expected to amount to approximately €108.1 million, representing a year-on-year decrease of approximately 15%.
For the first half of 2026, preliminary unaudited revenues are expected to total approximately €227.9 million, representing a year-on-year decrease of approximately 16%.
Just – Evotec Biologics (JEB)
For the second quarter of 2026, preliminary unaudited revenues for Just – Evotec Biologics are expected to amount to approximately €35.4 million, representing a year-on-year decrease of approximately 17%.
For the first half of 2026, preliminary unaudited revenues are expected to total approximately €72.3 million, representing a year-on-year decrease of approximately 29%.
Horizon and Strategic Priorities
Horizon remains Evotec's framework for the next phase of its transformation, focused on operational excellence, scientific leadership and commercial execution.
Since the launch of Horizon, Evotec has continued to advance measures to streamline operations, increase agility and focus resources on areas with the clearest path to value. The updated full-year 2026 outlook does not change the strategic direction of Horizon or the timeline for its implementation.
Evotec remains on track to deliver approximately 20-30% of cost savings in 2026 as part of its previously announced objective of €75 million in annual run-rate savings by the end of 2027.
The strategic review announced with the Q1 2026 results remains ongoing, and Evotec will provide a further update when appropriate.
Webcast Details
Evotec will host a webcast and conference call on Tuesday, July 14, 2026, at 2:00 p.m. CEST / 1:00 p.m. BST / 8:00 a.m. EDT.
To join the audio webcast and access the presentation slides, please register via this link .
An on-demand replay of the webcast will be available under the same link following the event and on Evotec's website .
Conference Call Details
To join the conference call, please pre-register via this link . Participants will receive a confirmation email containing dedicated dial-in details, including the telephone number, access code and PIN.
A simultaneous slide presentation for participants joining by telephone will be available under this link .
Downloads
![]()
About Evotec SE
Evotec is a life science company pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, Evotec accelerates the journey from concept to cure with greater speed, intelligence and precision. The company's expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms including Molecular Patient Databases, PanOmics and induced pluripotent stem cell-based disease modelling. Through flexible partnering models tailored to customers' needs, Evotec works with all Top 20 pharmaceutical companies, more than 800 biotechnology companies, academic institutions and other healthcare stakeholders. Evotec's offerings range from standalone services to fully integrated research and development programmes and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, the company is redefining biologics development and manufacturing to improve accessibility and affordability. With a portfolio of more than 100 proprietary research and development assets, most of which are co-owned, Evotec focuses on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology and immunology. Evotec's global team of more than 4,500 experts operates from sites in Europe and the United States, providing complementary technologies and services through a network of synergistic centres of excellence.
Learn more at www.evotec.com and follow Evotec on LinkedIn and X at @Evotec.
Forward-Looking Statements
This announcement contains forward-looking statements concerning future events, including Evotec's preliminary financial results, updated full-year 2026 outlook, expected commercial conversion, anticipated strategic partnership and milestone contributions, Horizon implementation, expected cost savings, liquidity, financial flexibility and future business performance. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of these words and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on information available to Evotec and on expectations and assumptions considered reasonable by the company at the time the statements were made. No assurance can be given that these expectations will prove correct. Forward-looking statements involve known and unknown risks and are based on assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond Evotec's control.
Evotec expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement to reflect changes in expectations, events, conditions or circumstances, except as required by applicable law.
Contact Us
+49 40 560 81 0
Follow Us
©2026, All rights reserved.
Notification of Major Holdings Page 1 | 5 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) Acquisition/disposal of shares with voting rights X Acquisition/disposal of instruments Change of breakdown of voting rights X Other reason Voluntary group notification with triggered threshold on subsidiary level 3. Details of person subject to the notification obligation Natural person First name Surname Date of birth Legal entity Name including legal form (entity) City of registered office Country The Goldman Sachs Group, Inc. Wilmington, DE United States of America (the) 4. Name(s) of shareholder(s) holding directly 3% or more voting rights, if different from 3. Name 5. Date on which threshold was crossed or reached 23/06/2026
Page 2 | 5 6. Total positions % of voting rights attached to shares (total of 7.a.) % of voting rights through instruments (total of 7.b.1. + 7.b.2.) Total of both in % (7.a.
Jun 30, 2026, Hamburg, Germany and Seattle, USA
Just – Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics
======================================================================================================
- Expands Just – Evotec Biologics partner-enablement and technology licensing model for proprietary continuous manufacturing platform
- Enables deployment of continuous manufacturing platform in partner-owned facilities to support higher productivity and flexibility compared with fed-batch technology biologics manufacturing
- Modular manufacturing infrastructure, equipment and proprietary technology enable rapid and cost-efficient increase in capacity for biologics manufacturing
Seattle, WA, USA / Hamburg, Germany June 30, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the expansion of its Just – Evotec Biologics services with J.TRAIN, a new offering that enables biopharmaceutical companies to deploy Evotec’s proprietary continuous manufacturing technology directly within their own facilities on a turnkey basis. J.TRAIN brings together prefabricated modular cleanrooms and industry-standard manufacturing equipment with Just – Evotec Biologics’ cGMP-compliant process automation, designed to enable significantly faster and more cost-effective deployment than traditional manufacturing expansion.
Linda Zuckerman, PhD, EVP Global Head of Just – Evotec Biologics commented:
“J.TRAIN is a disruptive opportunity for industry to increase capacity and manufacture biologics at reduced costs and improved productivity, with deployment in as little as 18 months. It exemplifies the strategic shift in Just – Evotec Biologics toward a rapidly deployable, capital-lighter and technology-focused business model. We now combine technology licensing with process design and engineering capabilities, enabling the fast establishment and implementation of the most advanced continuous manufacturing processes, giving companies greater, tunable control over clinical and commercial materials. The model was validated by our December 2025 transaction with Sandoz, which included the provision of a manufacturing facility alongside a license to our proprietary manufacturing technology, demonstrating both its feasibility and scalability.”
Unveiled in April 2026 at the INTERPHEX conference in New York City, J.TRAIN allows customers and partners to establish high-performance biologics manufacturing capacity on their own premises, effectively embedding advanced manufacturing capabilities directly into their operations. Proprietary automation scripts for continuous process control, as well as digital validation, documentation and training protocols are all designed to significantly streamline implementation and ensure regulatory readiness.
J.TRAIN represents a step change in productivity and efficiency compared to conventional fed-batch approaches. It can enable the production of more than 500 kilograms of drug substance from less than 10,000 square feet of cleanroom space, achieving productivity levels more than ten times traditional methods. This efficiency is expected to translate into substantially lower operating costs per unit mass while allowing production scale to be flexibly adjusted through the duration of manufacturing runs rather than the size of the facility. The integrated nature of the J.TRAIN design allows for rapid transitions between products, minimizing downtime and supporting multi-product manufacturing environments.
With deployment timelines of approximately 18 months, J.TRAIN offers a significantly faster pathway to capacity expansion compared to traditional biologics manufacturing facilities. This shorter build time positions the solution as a compelling alternative for companies seeking to rapidly increase manufacturing capabilities in response to growing demand.
Downloads
![]()
About Just – Evotec Biologics
Just – Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform company that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at www.just-evotecbiologics.com .
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of more than 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec .
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact Us
+49 40 560 81 0
Follow Us
©2026, All rights reserved.
-
-
-
Solutions
-
Company
-
IR & News
back
-
-
…
-
Annual General Meeting

Annual General Meeting
Recording of the Management Speech
Convocation Documents for Download
Annual General Meeting
Recording of the Management Speech
Convocation Documents for Download
Recording of the Management Speech
Convocation Documents for Download
Annual General Meeting
Recording of the Management Speech
Convocation Documents for Download
Ordinary Annual General Meeting 2026
The Annual General Meeting of Evotec SE was held on Thursday, 11 June 2026, 10:00 a.m. (CEST), at the CinemaxX Hamburg-Dammtor, Saal 1, Dammtordamm 1, 20354 Hamburg, Germany as an in-person event.
If you wish to view our Annual General Meeting archive you can do so here .
Agenda
- Presentation of the approved annual financial statements and the consolidated financial statements of Evotec SE as of 31 December 2025, as approved by the Supervisory Board, the management reports for Evotec SE and the Group for the financial year 2025, the report of the Supervisory Board for the financial year 2025 and the comments by the Management Board regarding this information pursuant to Sections 289a, 315a of the German Commercial Code (Handelsgesetzbuch, HGB).
- Resolution discharging the members of the Management Board of liability for financial year 2025.
- Resolution discharging the members of the Supervisory Board of liability for financial year 2025.
- Resolution regarding the election of the auditor of the consolidated financial statements and the auditor of the sustainability report for financial year 2026 and of the auditor for any review of additional financial information during the year
4.1 Election of the auditor of the the consolidated financial statements and of the auditor for any review of additional financial information during the year
4.2 Election of the auditor of the sustainability report - Resolution to approve the Remuneration Report 2025
- Resolution on expanding the Supervisory Board and the corresponding amendment to Article 9 (1) of the Articles of Association
- Resolution on new and re-elections to the Supervisory Board
7.1 Dr. Wolfgang Hofmann
7.2 Dr Duncan McHale
7.3 Dieter Weinand
7.4. Wesley Wheeler - Resolution on creating contingent capital for the issue of subscription rights to Management Board members of Evotec SE, members of management boards of affiliated companies in Germany and abroad and selected managers of Evotec SE and affiliated companies in Germany and abroad as part of a Performance Share Plan 2026 (PSP 2026), based on a resolution of authorisation and amendments to the articles of association.
a) Authorisation to issue stock options with subscription rights to Evotec SE shares
b) Contingent capital
c) Amendments to the Articles of Association
d) Discontinuation of the Share Performance Programmes 2015 and 2017 - Resolution to approve the revised remuneration system for the Management Board
Downloads
![]()
Recording of the Management Speech
Please find below the recording of the Management Speech at the Annual General Meeting 2026.
Youtube video consent fallback text.
If you cannot view the recording above, please watch the Annual General Meeting here .
Convocation Documents for Download
-
Corporate governance declaration for the 2025 financial year, PDF
-
Curriculum vitae of the candidates proposed for election on agenda item 7, PDF
-
Modified remuneration system of the Management Board on agenda item 9, PDF
-
Total number of shares and voting rights at the time of convening the Annual General Meeting, PDF
*Item 9 on the agenda was subsequently amended to include the proposed resolution. This amendment is based on the correction published in the Federal Gazette on May 7, 2026.
Proxy Voting
Further Downloads
Countermotions
There were no countermotions.
Confirmation of the vote count pursuant to section 129 (5) sentence 1 AktG:
Pursuant to section 129 (5) sentence 1 of the German Stock Corporation Act (AktG), the person voting may request confirmation from the company within one month of the day of the Annual General Meeting as to whether and how his or her vote was counted. A request to this effect may be sent by e-mail to: [email protected]
Jun 11, 2026, Hamburg, Germany
Evotec Reports Results of the Annual General Meeting 2026
=============================================================
- All agenda items adopted
- Dieter Weinand and Dr. Wolfgang Hofmann newly elected to the Supervisory Board
- Dieter Weinand appointed Chairman of the Supervisory Board
- Dr. Duncan McHale and Wesley Wheeler re‑elected to the Supervisory Board
Hamburg, Germany, June 11, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the results of its Annual General Meeting.
All agenda items put to vote were adopted by the Company’s shareholders with the required majority.
Shareholders elected Dieter Weinand and Dr. Wolfgang Hofmann to the Supervisory Board. Following the Annual General Meeting, the Supervisory Board appointed Dieter Weinand as its Chairman, succeeding Prof. Dr. Iris Löw-Friedrich. In addition, shareholders approved the re-election of Dr. Duncan McHale and Wesley Wheeler to the Supervisory Board.
Overall, 43.10% of the Company’s registered share capital was represented at the Annual General Meeting.
Further information on the Company’s Annual General Meeting, including the voting results on all agenda items, will be made available shortly on Evotec’s website .
Downloads
![]()
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of more than 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec .
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact Us
+49 40 560 81 0
Follow Us
©2026, All rights reserved.
Jun 2, 2026, Hamburg, Germany
Evotec Appoints Rui Wang as Head of Global In Silico and AI
===============================================================
- Transformational role shapes and executes global strategy for AI-driven, in silico innovation across the R&D continuum
- Brings more than 20 years of leadership shaping and executing enterprise data and AI strategies for mission-critical pharmaceutical and biotechnology operations
Hamburg, Germany, June 2, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the appointment of Rui Wang as Executive Vice President, Head of Global In Silico and AI. Mr. Wang brings to Evotec more than 20 years of experience supporting global pharma and biotech organizations to embed scalable data, analytics & AI across R&D, drug development, manufacturing and supply chain functions. In his role, Mr. Wang will spearhead the integration of computational science and data-driven decision-making across the R&D operation, with the goal of creating enterprise-scale solutions that ensure AI and in silico science become key pillars of the Evotec commercial value proposition.
Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:
“Rui will play a key role in our ongoing effort to make Evotec’s drug discovery and development enterprise a powerful engine of innovation, integration and operational efficiency. Advanced computational tools are essential to enhancing the value of both our business segments – Drug Discovery and Preclinical Development as well as Just – Evotec Biologics. These tools are not a separate entity but are embedded in everything we do to discover and develop new therapies.”
Mr. Wang most recently served as Head of Data, Analytics and AI at AstraZeneca, where he has held roles of increasing responsibility for more than a decade. Prior to that he held positions at European Molecular Biology Laboratory’s European Bioinformatics Institute and at Tangram Therapeutics (formerly e-therapeutics). He holds M.Sc. degrees in Bioinformatics from the University of Manchester and in System Design for Internet Applications from Newcastle University.
Rui Wang, Evotec’s incoming Head of Global In Silico and AI, added:
“The companies that will lead in AI-enabled drug discovery are those that learn from the right data, generated against the right biological questions, at scale. Evotec is uniquely positioned at the intersection of discovery, data and proprietary platforms. Our focus is to translate this position into a durable scientific advantage by concentrating on the capabilities where we can truly differentiate – scaling them with depth and rigor.”
Downloads
![]()
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of more than 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec .
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact Us
+49 40 560 81 0
Follow Us
©2026, All rights reserved.
· Q1 2026 financial performance: Full-year 2026 guidance confirmed; start to the year as expected with group revenues of €156.6 m (€166.9 m at CER); adj. Group EBITDA of -€21.9 m (-€18.9 m at CER) impacted by one-off effects and foreign exchange headwinds
· D&PD partnerships progress: Nomination of a first preclinical development candidate in Almirall collaboration; new Gates Foundation grants advancing tuberculosis discovery programs
· Horizon well on track: Implementation phase commenced with actions underway to streamline operations, reduce cost base and improve utilization; benefits expected to build through 2026
· Leadership update: Transition to Claire Hinshelwood as Chief Financial Officer, ensuring continued financial stewardship; appointment of Dr. Ingrid Müller as Chief Operating Officer, driving execution
· Investor and analyst webcast and conference call today: 2 p.m. CET / 1 p.m. GMT / 8 a.m.
· Nomination of Dr. Wolfgang Hofmann as independent Supervisory Board member to further strengthen oversight and governance capabilities
· Conclusion of cooperation agreement with MAK Capital following constructive discussions, reflecting Evotec’s commitment to open shareholder dialogue
· Annual General Meeting to vote on the appointments of Supervisory Board members and proposed expansion of Supervisory Board, supporting effective oversight and long-term value creation
Hamburg, Germany, April 29, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the nomination of Dr. Wolfgang Hofmann for election as an independent member of the Supervisory Board at the company’s upcoming Annual General Meeting (AGM) to be held on June 11, 2026. The AGM agenda also includes the previously announced nomination of Dieter Weinand as Chairman of the Supervisory Board, as well as a proposal to increase the size of the Supervisory Board from six to seven members.
Following constructive discussions, Evotec has entered into a cooperation agreement with MAK Capital Fund LP (“MAK Capital”), a key shareholder of the company.
· Paul Hitchin to step down as of April 30, 2026
· Claire Hinshelwood appointed to CFO role as of May 1, 2026
Hamburg, Germany, April 24, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced that Chief Financial Officer (CFO) Paul Hitchin will step down on April 30, 2026, for personal reasons unrelated to the company. The Supervisory Board has accepted Mr. Hitchin’s decision and expressed deep appreciation for his leadership and significant contributions to the company. Since March 1, 2025, he successfully led Evotec through a significant financial and strategic evolution.
Mr. Hitchin will be succeeded by Claire Hinshelwood, effective May 1, 2026. Ms. Hinshelwood has more than 30 years of experience in financial leadership positions, most recently as Group Chief Finance Officer of BMI Group. In this role, she transformed the company’s financial operations and delivered significant underlying improvements to its financial position during a period of challenging market conditions.
• 2025 financial performance at high end of guidance: Q4 and FY group revenues of €253.3 m and €788.4 m, respectively (Q4: €266.7 m, FY: €810.4 m at CER); adj. group EBITDA of €58.0 m and €41.1 m, respectively (Q4: €64.8 m, FY: €52.3 m at CER)
• Robust execution across key partnerships in D&PD: Including significant clinical progress with milestone payments in Bristol Myers Squibb and Bayer collaborations
• Just – Evotec Biologics evolution: Established position as a leading technology-centered biologics innovator demonstrated by landmark Sandoz transaction, BARDA agreement and Gates Foundation grants
• Horizon operating model transformation: Initiated with footprint reduction to 10 sites, establishment of Centers of Excellence and commercial leadership development; expected run-rate cost savings of ~€75 million by end of 2027 with first financial benefit visible 2H 2026
• Leadership Update: Appointment of Dr. Ashiq H.
· Evotec participated in 2022 Series B financing round of antibody drug conjugate developer
· Transaction marks continued execution of Evotec’s portfolio monetization strategy
Hamburg, Germany, April 7, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced that it is expected to receive approximately $100 million in upfront consideration upon closing of the sale of Tubulis GmbH to Gilead Sciences. Evotec is eligible to receive up to approximately $58 million in additional contingent consideration in line with its equity participation and subject to the achievement of specified milestones. Closing of the transaction is expected in the second quarter of 2026, subject to customary closing conditions. Further details of the transaction were announced today by Gilead Sciences and Tubulis.
Through its Evotec Ventures activities, Evotec holds a 3.14% equity stake in Tubulis. The company was an investor in Tubulis’ €60 million Series B financing round in May 2022, as well as a €128 million Series B2 round which closed in March 2024. Tubulis currently has two programs in clinical trials for high-need solid tumor indications.
· Strengthens Supervisory Board leadership to support Evotec’s transformation, with a focus on commercial execution, strategic partnerships and profitability
· Industry veteran brings more than 30 years of global pharmaceutical industry leadership experience across senior management, commercial, operational and strategic roles
Hamburg, Germany, April 7, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced that the Supervisory Board of Evotec SE has proposed the election of Dieter Weinand, M.S. as Chairman of the Supervisory Board at the June 11, 2026, Annual General Meeting. The nomination reflects Evotec’s continued commitment to strengthening commercial execution, strategic partnerships and long-term value creation.
Dieter Weinand is proposed to succeed Prof. Dr. Iris Löw-Friedrich, whose term as Chairwoman of the Supervisory Board will conclude at the end of the 2026 Annual General Meeting, in line with the company’s planned succession process.
Dr.
· Horizon advances multi-stage transformation initiated with Priority Reset in 2024 and establishes new operating model across three pillars: operations, science and commercial execution
· Operations: Global footprint further streamlined to 10 sites to simplify organizational structures and improve cost base
· Science: Centers of Excellence concentrate key expertise and innovation infrastructure to deepen scientific leadership and strengthen competitiveness in high-value segments
· Commercial execution: Upgraded commercial organization enables faster execution, clearer ownership and improved customer responsiveness
· New operating model designed to deliver greater agility and sustainable growth, enabling improved value creation
· Structural Horizon measures expected to generate ~€75 million run-rate savings by end of 2027
· New phased 2026-2030 mid-term framework introduced, aligned with transformation roadmap
· Investor and analyst webcast and conference call today at 3 p.m. CET / 2 p.m. GMT / 10 a.m.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Evotec SE
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| IDYN | 0.13% | 1,672 | $ 144.572K | Nov 16, 2026 |
| CORO | 0.09% | 171,685 | $ 14.846M | Nov 16, 2026 |
| DISV | 0.01% | 183,916 | $ 635.828K | Nov 12, 2026 |
| LCTD | 0.01% | 437 | $ 37.786K | Nov 16, 2026 |
| DFAX | 0.00% | 86,591 | $ 299.36K | Nov 12, 2026 |
| DFIS | 0.00% | 19,075 | $ 65.945K | Nov 12, 2026 |
| DFIC | 0.00% | 26,589 | $ 91.923K | Nov 12, 2026 |